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INTRODUCTION 
Severe traumatic events are often followed by the deve-
lopment of acute respiratory distress Syndrome (ARDS) or even 
multiorgan failure in case of additionally occuring septic 
complications (Nuytinck et al.,1986). In recent years, a 
nearly illimitable variety of humoral and cellular mediators 
has been described which a l l may contribute more or less to 
the posttraumatic organ failure (Schlag and Redl, 1987). 
Among these factors activated inflammatory cells such as po-
lymorphonuclear leukocytes (PMNL), monocytes/macrophages, 
lymphocytes or fibroblasts are supposed to play an essential 
role in the initiation and perpetuation of inflammatory pro-
cesses (Dittmer et al.,1986; Dwenger et al.,1986; Nuytinck 
et al.,1986; Joka et al.1987; Redl et al.,1987; Lammers et 
al.,1988). 
In the early posttraumatic phase mainly PMNL and mono-
cytes are attracted into the wound area and stimulated to 
phagocytosis of damaged tissue and invasive organisms. Düring 
this physiological repair, however, the phagocytizing cells 
release destructive enzymes and oxygen free radicals from 
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their phagolysosomes also extracellularly thus contributing 
considerably to the consumption of the body's antiproteoly-
t i c and antioxidative defence mechanisms. Especially libe-
rated proteinases (e.g. elastases, cathepsins) may overcome 
locally the inhibitory potential of their main antagonists, 
oc-Proteinase inhibitor (oCj-PI), <*
2
-macroglobulin and cy-
steine Proteinase inhibitors, thereby being able to destroy 
vital structural as well as humoral proteins. Such pathobio-
chemical reactions are suggested to be, at least in part, 
conducive to the maintenance of inflammation (Lang and F r i t z , 
1986). As shown previously (Jochum et al.,1986), the extra-
cellular amount of neutrophil elastase complexed to^L-PI in 
plasma can be taken as a reliable likeness of the PMNL acti-
vation in the wounded or infected area, whereas Stimulation 
of monocytes/macrophages is reflected by the serum concen-
tration of neopterin, a specific guanosinetriphosphate meta-
bolite excreted from activated mononuclear cells (Huber et 
al.,1987 a,b; Redl et al.,1987). 
Fibroblasts also play a dual role during the posttrau-
matic inflammatory response. On the one hand the recruitment 
of fibroblasts into the wound initiates the reparative phase 
of wound healing, whereby among other substances high amounts 
of type I and III collagens are synthesized to restore con-
nective tissue matrices. Those fiber-forming collagens are 
produced as procollagens with additional propeptide extensi-
ons at both ends. Before the mature molecules are deposited 
into the tissue the propeptides are cleaved off and libera-
ted into the extracellular f l u i d . Only recently i t could be 
demonstrated that the increase in the synthesis rate of type 
III Collagen in the granulation tissue after major abdominal 
surgery is high enough to be reflected by the increasing a-
mount of the N-terminal procollagen-III-peptide (P-III-P) in 
serum (Haukipuro et al.,1987). On the other hand, several 
lines of evidence suggest that the conversion of functional 
organ tissue (e.g. in liver or lung) to connective tissue is 
also indicated by elevated serum P-III-P levels and allows a 
rough quantification of the fibrosis grade of these organs 
(Surrenti et al.,1987; Mc Cullough et al.,1987; Lammers et 
al.,1988; Kirk et al.,1984). 
Here we describe a close follow-up measurement of plasma 
or serum levels of complexed neutrophil elastase, neopterin 
and P-III-P which may be indicative of organ failure subse-
quently to severe multiple trauma. 
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PATIENTS AND METHODS 
24 multiply injured patients (Injury Severity Score more 
than 30 points) with predisposition to ARDS were prospective-
ly studied up to 14 days after trauma. Increase of extravas-
cular lung water (EVLW) above 10ml/kg body weight (pulmonary 
arterial wedge pressure below 15mmHg) was taken as a main c r i -
terion of ARDS (Joka et al.,1987). Septic complications and 
hepatic failure (total serum bilirubin above 34jjmol/l) were 
diagnosed according to Goris et al.(1985). 
Blood samples were drawn 4times per day up to 48 hours 
post trauma and thereafter once a day t i l i to the end of the 
Observation period. The specimens were processed either to 
plasma or to serum and kept frozen at -70 C until use. Com-
plexed neutrophil elastase in plasma was assayed by an ELISA 
test kit (PMN Elastase, E.Merck, Darmstadt; upper normal 
ränge: 180 ng/ml). The RIA technique was applied for the de-
termination of D(+)neopterin in serum (Neopterin-RIAcid/se-
rum, Henning, Berlin; normal ränge: 6-10nmol/l) as well as of 
P-III-P in plasma (RIA-gnost Prokollagen-III-Peptid, Behring-
werke, Marburg; normal ränge: 3-15ng/ml). Total serum b i l i -
rubin was quantified with a test combination of Boehringer, 
Mannheim (upper normal ränge: 17jimol/l). 
RESULTS 
Twelve of the 24 patients studied had to be allocated to 
the ARDS group according to the rise of EVLW above the pro-
spectively established limit of 10ml/kg b.w. during the early 
(48 hours) or late (from day 4 onwards) Observation period. 
Whereas a l l patients of this group developed moderate to se-
vere septic complications and hepatic failure (total b i l i r u -
bin well above 34}jmol/l), only 4 patients without acute re-
spiratory disease showed minimal transient signs of bacterial 
infection. However, in about 80% of the non-ARDS patients to-
tal serum bilirubin was moderately elevated above normal in-
dicating impairment of liver function. 
As demonstrated in Fig. 1 increased release of neutrophil 
elastase could be assayed in both groups already in the f i r s t 
blood sample (time 0) taken at least within two hours after 
trauma. In plasma of patients without development of ARDS ma-
ximal elastase liberation was evident 6 hours later followed 
by a rapid normalization. ARDS patients showed highly elevated 
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plasma levels of complexed elastase up to the 7th posttrauma-
t i c day. Even at the end of the Observation period these va-
lues did not decline to the normal ränge. 
Fig. 1: Posttraumatic plasma/serum levels (median +. pseudo SE) 
of elastase in complex with<x.-proteinase inhibitor 
(E-oc.PI), neopterin and procollagen-III-peptide (P-III-F 
in patients with or without acute respiratory distress 
Syndrome (ARDS). 
Increase of neopterin respectively P-III-P levels above 
normal was evident only from the second posttraumatic day on-
wards (Fig.1). Neopterin serum concentrations reached a f i r s t 
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maximum about 6 days post trauma in both groups; thereafter 
an additional significant rise was seen in ARDS patients t i l i 
the end of the study period, whereas in the non-ARDS collec-
tive a slight decrease was measurable. P-III-P levels in-
creased steadily without significant differences in both pa-
tient groups up to the 14th posttraumatic day. 
Case Reports 
Fig. 2 shows the sequential plasma/serum levels of the 
above mentioned Parameters in 4 individual cases. 
Fig. 2: Posttraumatic plasma/serum levels of complexed ela-
stase, neopterin, procollagen-III-peptide (P-III-P) 
and bilirubin in individual Polytrauma patients. 
In patient 334 the accident caused severe lung and liver 
contusion. ARDS and sepsis was diagnosed at the 4th posttrau-
matic day; the patient died at the 7th day due to irreversi-
ble lung, li v e r and kidney f a i l u r e . The severe c l i n i c a l cöurse 
is closely reflected by the highly elevated and repetitively 
increasing elastase levels during the whole Observation period 
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as well as by the tremendously rising concentrations of neo-
pterin, bilirubin and P-III-P from the second day onwards. 
In contrast, patient 336 did not develop ARDS despite 
severe lung contusion. Apart from tracheal germs, which were 
sufficiently treated with antibiotics from the 6th posttrau-
matic day t i l i recovery, no septic complications or organ 
failure occured. The i n i t i a l trauma-induced elastase release 
was followed by a rapid normalization, the minor signs of the 
local infection seem to be reflected by a small additional 
increase of complexed elastase and a more retarded transient 
extracellular secretion of neopterin. Although the slightly 
elevated bilirubin levels between day 4 and 8 indicate only 
minor liver dysfunction, the P-III-P plasma concentrations 
rose remarkably u n t i l l the end of the study phase. 
Patients 337 and 338 also sustained severe lung contu-
sions. In patient 337 the traumatic event was followed imme-
diately by manifestation of ARDS and was further complicated 
by liver dysfunction - the latter being indicated by a stea-
dily increase in total serum bilirubin - were present t i l i 
to the end of the study period. The development of the infec-
tious complications are indicated by the consistently high 
elastase levels in the early phase and the repeatedly release 
of the PMNL protease in the later posttraumatic phase. A 
significant increase of the neopterin and P-III-P levels is 
evident between day 5 and 8. The patient recovered from the 
multiorgan dysfunction about 7 weeks after trauma. Patient 
338, in contrast, did not develop life-threatening long-term 
organ f a i l u r e . After an early c l i n i c a l normalization, which 
is reflected also in the rapid decline of extracellular ela-
stase release, a transient septic period from day 5 to 11 was 
accompanied with moderate respiratory insufficiency. There-
after the patient convalesced without further complications. 
The sepsis-like phase was paralleled by increasing elastase 
levels as well as by a slight elevation of neopterin and 
P-III-P in the circulation. Total serum bilirubin was only 
modestly and temporarily increased. 
DISCUSSION 
In recent years, a great number of studies have focused 
on the role of neutrophils as a prominent source of powerful 
mediators in the acute inflammatory process initiated by Po-
lytrauma or major surgery. With respect to the proteases re-
leased extracellularly from the activated PMNL c e l l s , sequen-
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t i a l measurements of complexed elastase in plasma turned out 
to be a helpful tool in early diagnosis of septic complica-
tions and the grading of the severity of septicemia (Jochum 
et al.,1986, Nuytinck et al.,1986, Inthorn and Jochum,1988). 
As shown in this paper, the primary activation of the PMNL 
immediately after the polytraumatic event is followed by re-
petitive increases of elastase in plasma in those patients 
who developed ARDS and additional organ f a i l u r e . Since this 
multiple organ insufficiency in our patients was mainly due 
to septic complications, we cannot confirm the former State-
ment of Nuytinck et al.(1986) and Redl et al.(1987) that ARDS 
per se is indicated by elevated plasma levels of complexed 
PMNL elastase. In agreement with these authors, however, the 
involvement of the monocyte/macrophage System in sepsis-re-
lated ARDS could be proven. Neopterin, an activation marker 
of the lymphocyte/macrophage axis as well as of the direct 
action of bacterial endotoxins on the mononuclear cells 
(Huber et al.,1987b), significantly increased in the circu-
lation even before severe sepsis became manifest. Transient 
signs of infection were indicated only by a minor rise of the 
neopterin serum levels. Neither the traumatic event per se nor 
the severity of the trauma was reflected by neopterin which 
is in contrast to the behaviour of PMNL elastase as demonstra-
ted recently by Dittmer et a1 -(1986). 
Conflicting results have also arisen concerning P-III-P 
excretion to the circulation as a valuable sign of liver (Sur-
renti et al.,1987; Mc Cullough et al.,1987) and/or lung f i -
brosis (Kirk et al.,1984; Lammers et a l . , 1988) in acute and 
chronic diseases. Moreover, elevated posttraumatic P-III-P 
plasma levels may only indicate physiological wound healing 
(Haukipuro et al.,1987). From our data the latter can be de-
duced at least for those patients who did not develop organ 
failure in the posttraumatic course. On the other hand, in 
most of the patients with infaust multiorgan insufficiency 
P-III-P levels increased clearly above the maximal median va-
lue (60 ng/ml) of the non-ARDS group some time before lethal 
outcome. Therefore, highly elevated P-III-P plasma concentra-
tions may be a reliable marker of bad prognosis due to massive 
organ f i b r o s i s . The threshold value, however, has to be eva-
luated in further studies. 
In conclusion, measurement of sequential plasma levels 
of cell-derived inflammation mediators turned out to be a 
helpful tool for early diagnosis of severe posttraumatic mul-
tiorgan f a i l u r e . 
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sepsis, 602, 605 
Atrial pressure, left, pulmonary venous 
hemodynamics and gas exchange 
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cell-mediated immune effects, 
496, 497, 499, 501, 502 
multiple trauma, early events, 507-509 
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cascade of cell-mediated immune 
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respiratory distress, 867, 868, 870, 
871 
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Polytrauma, 743, 745 
lymphocyte/monocyte ratio in 
survival, 769 
Biologically active site, C3a, 299 
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endotoxin shock effects, 931-935 
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embolism, 39-41 
Bradykinin antagonist B4148, blood 
pressure maintenance, endotoxin 
shock, 983-987 
Brain, PAF antagonist inhibition of induced 
shock, 430 
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amino acid concentrations, serum, 
experimental endotoxin shock, 
595, 598 
metabolic abnormalities in sepsis, 539, 
540 
Bronchoalveolar lavage, ARDS, 13, 19, 20, 
22, 23, 44 
exogenous Surfactant, 795 
Bronchoconstriction, WEB 2086 (PAF 
antagonist), anaphylactic lung 
reaction, 925, 926, 928 
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dopamine infusion, effect evaluation 
with systolic time intervals, 
1101-1105 
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endotoxin and overwhelming 
inflammatory response of early 
sepsis, 372-374 
enteric translocation of microorganisms, 
377-380 
scalded rats, 379 
sheep, 378 
PAF antagonist inhibition of induced 
shock, 431 
scalded pig, 455-461 
sepsis after, TP-5 immunomodulation, 
995-998 
Butyrophenones, 755 
BW 755C, glucose turnover in sepsis, 552, 
553 
C3 
activated, DIC in septic shock, 271-274 
IgG breakdown in Peritonitis exudate, 
527-532 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769, 770 
plasma, and abdominal sepsis prognosis, 
720, 721 
C3a, 7, 204 
activation 
endotoxin role in sepsis, 278-280 
MSOF pathogenesis in septic shock, 
dogs, 296 
pulmonary hypertension and vascular 
leakage, 283 
alveoli in, post-trauma, 43-47, 52 
ARDS, 299, 880 
biologically active site, 299 
circulation, peripheral, septic shock, 170 
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corticosteroids to prevent formation, 
total hip arthroplasty, 879-882 
ELISA quantitation with monoclonal 
antibodies, 299-303 
cf. C3, 300-303 
endotoxin and overwhelming 
inflammatory response of 
early sepsis, 372, 373 
in MSOF, 296, 880 
acute pancreatitis, 265-268 
Polytrauma, 414 
postoperative/posttrauma, 
biochemical analysis and 
scoring, 650, 651 
prognostic index in sepsis, 635 
rheumatoid arthritis, 299 
systemic lupus erythematosus, 299 
C3c, complement activation, MSOF 
pathogenesis in septic shock, dogs, 
292, 294-296 
C4 
complement activation, endotoxin role in 
sepsis, 279, 280 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769, 770 
plasma, and abdominal sepsis prognosis, 
720, 721 
C5a, 7, 13, 43, 44, 46, 115, 116, 204, 825 
activation 
endotoxin role in sepsis, 278-280 
MSOF pathogenesis in septic shock, 
dogs, 292, 296 
pulmonary hypertension and vascular 
leakage, 283, 284 
corticosteroids to prevent formation, 
total hip arthroplasty, 879-882 
MSOF in acute pancreatitis, 265-268 
terminal complement complexes, 
266, 267 
and PAF, 366 
C5b9, 266 
Cachectin. See Tumor necrosis factor (TNF, 
cachetin) entries 
Calcium 
capillary endothelial cells, 159 
endothelium permeability effects, 127— 
131 
endotoxin-induced intracellular overload, 
1053-1061 
hepatocytes, protein kinase C and 
diacylglycerol accumulation, 
endotoxemia, 575, 578, 584 
isolated heart, effect of L M W plasma 
fraction in hypovolemic traumatic 
shock, 234 
overload in ischemic cell death, 
1065-1066 
and PAF, 366 
rapid influx and toxic action, 68 
Calcium antagonists in shock/ischemia, 
1060, 1065-1073 
ATPase, 1065, 1066 
calcium overload in ischemic cell death, 
1065-1066 
endotoxin shock, 1068-1071 
glucose deficiency, 1066 
hemorrhagic shock, 1067 
mechanisms of action, 1072 
magnesium, 1072 
mitochondrial function, 1066 
muscle spasm, smooth, 1066 
phospholipase, 1066, 1071 
platelet aggregation, 1066 
traumatic shock, 1067-1068 
see also specific agents 
Calcium gates, 119, 120 
Calmodulin, 120 
Calvin, John, 850 
Cancer patients, 493-494 
Candida tropicalis, in vitro phagocytosis 
assay, 508, 510 
Candidiasis, systemic, 378 
Capillary endothelium 
contractile elements, 157-160 
endotoxemia and shock, impaired 
regulation, 157-160 
lung, complement activation, MSOF 
pathogenesis in septic shock, 
dogs, 292, 294-296 
Capillary permeability. See under 
Permeability 
Capillary pressure, lung edema, 28 
Capillary surface area reduction, ischemia 
and circulatory system in MSOF, 
1082 
Carbon dioxide, arterial, metabolic 
abnormalities in sepsis, 537, 538; see 
also Respiratory quotient (C0 2 / 0 2 
exchange ratio) in shock 
Carbon monoxide, a-
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Cardiac function 
heart cells, cultured, effects of 
Pseudomonas aeruginosa toxins, 
rat, 247-251 
muscle p0 2 role, critically ill patients, 
139 
see also Heart entries 
Cardiac index, 625, 626 
extravascular lung water 
altered fluid regimen, advanced 
septic shock with acute 
respiratory failure, 804-806 
large volume replacement with 
crystalloids, 810, 811 
hydroxyethyl starch, volume replacement 
in ovine endotoxemia, 818, 819 
Immunoglobulin and plasmapheresis 
therapy, hemodynamic effects 
during treatment for septic shock, 
1026, 1027 
pulmonary vascular resistance, ARDS in 
septicemia, 175-179 
pulmonary venous hemodynamics and 
gas exchange disturbances, E. 
coli septicemia, Goettingen pig, 
185, 186 
Cardiac Output 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 202 
circulation, peripheral, septic shock, 
163-166 
hemofiltration and survival time, porcine 
acute endotoxic shock, 822, 825 
ischemia and circulatory system in 
MSOF, 1076-1077, 1080, 1082 
oxygen supply-uptake relationship, 
septic shock, 183 
PAF effects in sheep, 448-449 
septic shock, chacma baboom (Papio 
ursinus), 207, 210-215, 219-222 
Cardiac work, septic shock, heart 
overperformance in, 260-262 
Cardiogenic shock, scoring Systems, 
625-630 
CI and SVR, 625, 626 
Cardiopulmonary arrest, lipid peroxidation 
inhibition, 891-895 
Cardiopulmonary response to endotoxin 
eicosanoids in, sheep, 201-204 
free radical scavengers, 885-888 
Catalase, 201-202, 887 
Catecholamines, 755, 756 
glucose turnover in sepsis, 552-553, 
557, 559 
ischemia and circulatory system in 
MSOF, 1077 
see also specific catecholamines 
Cathepsin D, 431, 168 
Cathepsin G, 937, 941, 942 
Cement, methylmethacrylate, 879, 880 
Cerebrocortical perfusion, RA642 effects, 
hemorrhagic shock, 1091-1094 
Ceruloplasmin, changes in MSOF and 
ARDS, 331-337 
C-reactive protein, 335, 336 
number of organs involved, 333, 334, 
336 
Ci-esterase inhibitor 
circulation, peripheral, septic shock, 
170-171 
complement activation, endotoxin role in 
sepsis, 278, 280 
lymphocyte/monocyte ratio in 
Polytrauma survivial, 769 
plasma, and abdominal sepsis prognosis, 
720 
Chemiluminescence-inducing radicals, 
339-344; see also Oxygen radicals 
Chemotactic factors, alveolar macrophages, 
20 
Chemotaxis, 4-hydroxy-nonenal, 351 
Chioramphenicol, 852 
Cholecystectomy, 493 
Cholecystokinin, 380 
Cholinesterase, scintigraphic evaluation of 
posttraumatic liver function, 777 
Chromatography 
HPLC, PAF effects in sheep, 448-451 
ion exchange, positive inotrophic 
factor as myocardial stimulant, 
254-255 
Chronotropic effect, negative, a-
mercaptopropionylglycine in 
hemorrhagic shock, 902 
Chymase, mast cell, 937, 941, 942 
Cimetidine, 755 
Circulating immune complexes, and 
abdominal sepsis prognosis, 716 
Circulation, peripheral, septic shock, 
163-171 
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blood flow redistribution, 164 
blood volume redistribution, 164-165 
cardiac Output, 163-166 
oxygen utilization, 163, 167-169 
pathogenesis, 169-171 
peripheral vascular failure, 165-167 
permeability, microvascular, 167 
systemic vascular resistance, 163-166, 
168, 170 
Clostridium, 1008, 1020 
sordelli, 1018 
Clotting factor infusion, MSOF prognostic 
indices, logistic regression analysis, 
644 
Coagulation cascade, 31, 318-319 
fibrinolysis, and kallikrein system, 
MSOF, postoperative/posttrauma, 
biochemical analysis and scoring, 
652-654 
lung, 6 
microvascular bed, cell interactions 
in septic shock, 115 
methylprednisolone pretreatment effects 
in porcine E. coli endotoxemia, 
873 
pulmonary vascular permeability, 
305-307 
septic patients, 383-387 
see also Disseminated intravascular 
coagulation; specific components 
Collagen III propeptide, 665 
ARDS, posttraumatic, prognosis, 
674-679 
Colloid osmotic pressure, plasma, 
extravascular lung water, large 
volume replacement with 
crystalloids, 810-812 
Compensated shock, hemorrhagic shock, 
phase-related vascular reactivity, 
cats, 144-148 
Complement, 31 
ARDS, 43 
cascade 
lung, microvascular bed, cell 
interactions in septic shock, 
115, 116 
MSOF, postoperative/posttrauma, 
biochemical analysis and 
scoring, 650-651 
and endotoxin role in sepsis, 
277-281 
Igs, therapeutic, phagocytosis 
Stimulation, Peritonitis, 1039, 
1041 
and immune suppression, post-surgical 
or post-traumatic, 492 
lung in shock, 4, 5, 7, 13 
hypertension and vascular leakage, 
rabbit, 283-286 
vascular permeability, 305, 306 
MSOF pathogenesis, septic shock, dogs, 
291-296 
pathway, classical cf. alternative, MSOF 
pathogenesis in septic shock, 
dogs, 293 
PMNs, 20 
prognostic index in sepsis, 633, 634 
septic shock, 169-170 
see also specific components 
Complement complexes, terminal 
acute pancreatitis, 266, 267 
pulmonary hypertension and vascular 
leakage, 283-286 
Contractile elements, capillary endothelial 
cells, 157-160 
Contractility 
and cardiac function, Pseudomonas 
aeruginosa toxins, 247 , 248 
heart Performance during septic shock, 
awake sheep, 238 
Coronary artery disease, 1079, 1080 
Corticosteroid(s) 
nebulized, in experimental respiratory 
distress, 867-871 
aveolo-capillary interface, 867 
antithrombin III, plasma, 869-871 
beclometasondipropionate (BDP), 
867, 868, 870, 871 
crystalloid infusion, 868 
Superoxide, PMN production, 869, 
870 
for septic shock with ARDS, 857, 
860-864 
dexamethasone, 861 
methylprednisolone, 861-863 
severity of underlying disease, 858 
V A comparative study of severe sepsis, 
840-844, 847-855, 862-863 
encephalopathy, 841, 843, 853-855 
entry criteria, 853 
inflammation pathways, 850-851 
mortality, 842 
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cf. previous trials, 852 
rationale of therapy, 851, 852 
sepsis criteria, 841 
trial design, 852-853 
see also specific drugs 
Cortisol, sepsis, 753, 755 
C reactive protein, 665 
cerulosplasmin changes in MSOF and 
ARDS, 335, 336 
immune suppression, post-surgical or 
post-traumatic, 492 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769 
plasma, and abdominal sepsis prognosis, 
716, 717 
Creatinine 
dopamine and renal function, 1098 
Polytrauma, 743, 745 
Crossed immunoelectrophoresis, C3 and 
IgG breakdown in Peritonitis 
exudate, 529, 531 
Crystalloids 
corticosteroid, nebulized, in 
experimental respiratory distress, 
868 
cf. hydroxyethyl starch, volume 
replacement in ovine 
endotoxemia, 815-819 
large volume replacement with, E V L W 
in septic shock, 809-813 
c-sis, neutrophils, thrombin-induced 
adhesion with endothelial cells, 
109 
CTP:phosphocholine citidyl transferase, 576 
Cutaneous thermal injury. See Burn(s) 
CV-3988, 428, 430, 442, 485 
CV-6209, 426 
Cyclic nucleotides, lung, endotoxin-induced 
microvascular endothelial injury, 95, 
97 
Cycloheximide, 122 
liver, perfused, sepsis effect on 
metabolism, 590, 591 
Cyclooxygenase inhibition 
cardiopulmonary response to endotoxin, 
eicosanoids in, 202, 203 
lung injury in E. coli endotoxemia, 
365-366 
Cysts, honeycomb, 29, 32 
Cytotoxic processes, effects, platelet 
activating factor antagonists, 443-
444 
Cytoxan, 377 
Dazoxiben, 365 
D-Dimer, fibrinolysis, 383-386 
Decompensated shock, hemorrhagic shock, 
phase-related vascular reactivity, 
cats, 145-148 
Decontamination, G l tract, multiple organ 
failure prevention, zymosan-induced 
Peritonitis, 827-832 
Delayed-type hypersensitivity 
Ig prophylactic therapy after cardiac 
surgery, 1031-1033, 1035 
T-cell-mediated immune suppression 
after Polytrauma, 518, 519 
2-Deoxyglucose tracer, metabolic 
abnormalities in sepsis, 549-551 
Dexamethasone, 121, 122 
corticosteroids for septic shock with 
ARDS, 861 
Dextran sulfate, 653 
Diabetic angiopathy, 1008, 1009 
Diabetic microangiopathy, 1009 
Diacyglycerol accumulation, hepatocytes, 
endotoxemia, rats, 575-586 
in situ receptor autoradiography, 579, 
583-584, 586 
phorbol ester binding sites, 583-584 
Dialysis, MSOF prognostic indices, logistic 
regression analysis, 644, 645 
Dichloroacetic acid therapy, metabolic 
abnormalities in sepsis, 540, 541 
Diiodotyrosine (DIT), sepsis, 752-754, 756 
leucocyte phagocytic activity, marker 
for, 711-713 
Diisofluorophosphate-a-thrombin, 
neutrophils, cf. thrombin-induced 
adhesion with endothelial cells, 103, 
104 
Diltiazem and endotoxin-induced 
intracellular C a 2 + overload, 
1053-1061 
epinephrine, 1057-1059 
hepatocytes, cytosolic C a 2 + in, 
1055-1060 
muscle, skeletal, 1054-1061 
Dimethylthiourea, 887 
Dipyrimadole (RA8), effects on 
Index / 1115 
cerebrocortical perfusion, acute 
hemorrhagic shock, 1091-1094 
Disseminated intravascuiar coagulation, 
383, 386 
endotoxin, dose-related effects on RES, 
410 
endotoxin-induced, antithrombin III-
heparin complex, 977-981 
fibrinolysis Syndrome, 971, 972, 974 
reticuloendothelial Stimulation to protect 
against, 1001-1005 
septic ARDS, 59 
and multiple system organ failure, 
62, 63 
in septic shock, activated C3, 271-274 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 479, 
480 
Dopamine 
kidney function, 1097-1099 
long-term administration and tolerance, 
1097-1099 
hemodynamics, 1098 
cf. RA642, effects on cerebrocortical 
perfusion, acute hemorrhagic 
shock, 1091-1094 
sepsis, 755 
systolic time interval evaluation, 
1101-1105 
Doppler flowmetry, laser RA642 effects on 
cerebrocortical perfusion, acute 
hemorrhagic shock, 1091-1094 
DPPC:egg PG, Surfactant, exogenous, 798 
DPPC in Surfactant, C3a and alveoli in, 
post-trauma ARDS, 44, 45 
DTPA and gamma-scintillation, alveolar 
permeability increased by PMA-
stimulated neutrophils, rabbits, 
ARDS, 324-327 
Edema, lung. See Pulmonary edema 
Eglin C 
endotoxin shock, ineffectiveness in, 
953-957 
pulmonary vascular permeability, 311 
septic shock, 945-948 
Eglin C/hirudin, recombinant, 
proteinase/protease inhibitor therapy, 
937-942 
Eicosanoids 
cardiopulmonary response to endotoxin, 
sheep, 201-204 
pulmonary vascular permeability, 
mediators, 305, 306, 308, 312 
see also Arachidonate/arachidonic acid 
metabolism; specific eicosanoids 
Elastase-a,-antiproteinase complex, 7, 8 
with antithrombin (EAT), humans, 
971-974 
early indicator of pediatric systemic 
infection, 689-693 
endotoxin and overwhelming 
inflammatory response of early 
sepsis, 372, 373 
immunoassay, automated homogenous 
enzyme immunoassay, 707-710 
cf. coated tube ELISA, 708-710 
intensive care unit assay, validity, 
701-705 
correlation to MOF score, 
704-705 
correlation to physicians 
Classification, 703-704 
ELISA, 701-702 
IMAC assay, 702 
kallikrein-kinin system components in 
ARDS after Polytrauma, 737, 
738, 741, 742 
marker for perioperative infection risk 
monitoring, validity of ELISA, 
695-700 
total leukocyte counts, 699, 700 
mediation of pulmonary vascular 
permeability, 308-310 
MSOF, Polytrauma, 414, 656-659 
and neopterin, plasma levels in MSOF, 
683-687 
and prognostic index in sepsis, 634 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 470, 
477-478, 480 
see also PMN elastase 
Elebute and Stoner Sepsis Score, 626-630, 
638, 664, 1026, 1027, 1029 
Electrical Stimulation, efferent, isolated 
intestinal vascular bed, hemorrhagic 
shock, phase-related vascular 
reactivity, cats, 145 
ELISA, 695-700 
coated-tube, 708-710 
1116 / Index 
Proteinase inhibitor, leukocyte neutral, 
945-946 
quantitation with monoclonal antibodies, 
C3a, 299-303 
cf. C3, 300-303 
Elongation factor-2, ADP ribosylation, 
Pseudomonas endotoxin A , 250 
Embolism, fat, pulmonary, 10, 37-41 
Hannover Polytrauma Score, 38 
histologic appearance, 40 
Injury Severity Score, 38 
long-bone or pelvis fracture, 39-41 
respiratory failure, 37, 41 
Encephalopathy, corticosteroids 
(glucocorticoid), V A comparative 
study of severe sepsis, 841, 843, 
853-855 
Endobulin, 1048, 1050 
Endocrine secretion patterns, sepsis, 
751-756 
A D H , 751, 753, 755, 756 
prolactin, 751, 753-754, 756 
thyroid hormones, 751-756 
Endothelial cells, thrombin-induced 
adhesion with neutrophils, 101-109 
Endothelial injury, endotoxin-induced, 
91-97 
grading, 84-85 
Endothelial proliferation inhibiting capacity, 
endotoxin and overwhelming 
inflammatory response of early 
sepsis, 373, 374 
Endothelial sWelling, lung in shock, 8, 9, 
11 
Endothelium 
arachidonate/arachidonic acid 
metabolism, 119-123 
permeability in vitro, bacterial toxins 
and calcium effects, 127-131 
see also Vascular intima in endotoxin 
shock 
Endothelium-derived relaxing factors, 157 
Endotoxemia 
HES volume replacement, 815-819 
lung injury in, 357-368 
failure, 12 
phases I-III, 885-888 
oxygen free radicals, 886-888 
recombinant human SOD in, 913-917 
and shock, impaired regulation, capillary 
endotheliala cells, 157-160 
Endotoxin, 850 
antithrombin III-heparin complex, DIC, 
977-981 
arachidonate/arachidonic acid 
metabolism, 119-123 
complement activation, 277-281 
MSOF pathogenesis in septic shock, 
dogs, 291 
effect, healthy volunteers, heart 
dysfunction cf. septic shock, 
196-197 
free radical scavengers and 
cardiopulmonary response, 
885-888 
granulocyte effects, lung, microvascular 
bed, cell interactions in septic 
shock, 114-116, 118 
granulocyte-endothelial cell adherence, 
123-124 
heart cells, cultured, effects of 
Pseudomonas aeruginosa toxins, 
rat, 247-251 
inflammatory reaction, G l tract 
decontamination, MOF 
prevention, 832 
inotropic effect in isolated rabbit heart, 
225-230 
oxygen delivery, 227 
perfusion circuit, 226, 227 
ventricular pressure cf. perfusion 
flows, 227, 228 
metabolic abnormalities in sepsis, 
550 
microvascular endothelial injury, 91-97 
MSOF, postoperative/posttrauma, 
biochemical analysis and scoring, 
654-655 
antibody levels, 645-655 
norole in MSOF, 419-423 
and overwhelming inflammatory 
response of early sepsis, 371-375 
endothelial proliferation inhibiting 
capacity, 373, 374 
oxygen supply-uptake relationship, 
septic shock, 181-183 
plasma concentrations related to 
responses, pig, 389-393 
Index / 1117 
plasma contact system factors, in vitro 
interactions, 401-405 
arterial 0 2 tension, 391-392 
hemodynamics, 390-391 
kallikrein-kinin system, 389, 390, 
392, 393 
prognostic value in sepsis, 634, 635, 
637 
lethality, 639, 640 
thrombocyte counts, 637-641 
proteases in MSOF due to septicemia, 
315-321 
renal microthrombosis, 916 
reticuloendothelial system, dose-related 
effects, 407-411 
structure and biological activity, 79-81 
and TNF, 463, 464 
see also Antibodies, anti-LPS and anti-
lipid A, determination with 
immunoblotting; specific bacteria 
Endotoxin shock 
amino acid concentrations, serum, 
595-599 
animal model development for shock, 
836 
calcium antagonists in shock/ischemia, 
1068-1071 
eglin C ineffectiveness, 953-957 
fibrinolytic functional determinants, pig, 
395-399 
hemofiltration and survival time, 
821-826 
hirudin/eglin C, recombinant, 937-942 
PAF antagonists, 428-429, 931-935 
proteinase/protease inhibitor therapy, 
937-942 
cf. traumatic shock, 941 
vascular intima in, 77-87 
WEB 2086 (PAF antagonist), cf. in 
anaphylactic lung reaction, 925, 
927, 928 
Enteric translocation of microorganisms, 
burns, 377-380 
scalded rats, 379 
sheep, 378 
Enterobacteriaceae, 827-832 
Eosinophil cationic protein, 22 
Epidermal growth factor, 380 
Epinephrine 
diltiazem and endotoxin-induced 
intracellular C a 2 + overload, 
1057-1059 
metabolic abnormalities in sepsis, 54, 
548 
Epithelial lining fluid, ARDS, C3a and 
alveoli in, post-trauma, 44 
Escherichia coli, 420, 426, 429, 538, 539, 
546, 547, 551, 557, 561, 723, 881, 
940 
animal models for shock, 836-837 
antibodies, anti-LPS and anti-lipid A , 
determination with 
immunoblotting, 1043-1049 
endotoxin, activated C3 in DIC in septic 
shock, fulminant meningococcal 
meningitis, 271, 273 
hemolysin injury, septicemia in, lung, 
67-70 
transmembrane pores, 69 
sepsis, kidney metabolism in, 
601-605 
see also Endotoxemia; Septicemia; 
Septic shock 
Expired minute volume, respiratory quotient 
(C0 2 / 0 2 exchange ratio) in shock, 
613, 614, 619-621 
Extravascular lung water (EVLW) 
altered fluid regimen, advanced septic 
shock with acute respiratory 
failure, 803-808 
cardiac index, 804-806 
microvascular integrity, 806 
plasma colloid osmotic pressure, 
803-808 
pulmonary artery pressure, mean, 
804 
pulmonary artery wedge pressure, 
803-808 
ARDS, posttraumatic, prognosis, 675 
and chemiluminescence-inducing 
radicals, porcine septic shock, 
340, 342 
hemofiltration and survival time, porcine 
acute endotoxic shock, 822, 823, 
825 
large volume replacement with 
crystalloids, septic shock, 
809-813 
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MSOF, Polytrauma, 414, 415 
recombinant hirudin/eglin C, endotoxin 
shock, 938, 939, 941 
Factor XII (Hageman factor), 384 
and endotoxin 
interactions with plasma contact 
system factors, 402, 404 
overwhelming inflammatory response 
of early sepsis, 372 
kallikrein-kinin system components in 
ARDS after Polytrauma, 737, 
738, 741 
Factor Xl la , circulation, peripheral, septic 
shock, 171 
Fat embolism after bone fracture, 10, 37-41 
Fat metabolism 
respiratory quotient ( C 0 2 / 0 2 exchange 
ratio) in shock, 619-621 
in sepsis, 536-539, 545 
Fentanyl, 755 
Fibrin 
endotoxic shock, fibrinolytic functional 
determinations, pig, 395, 399 
lung organ failure, 10, 11 
Fibrinogen 
consumption, recombinant hirudin/eglin 
C, endotoxin shock, 937-942 
endotoxic shock, fibrinolytic functional 
determinations, pig, 395-399 
plasma 
endotoxin-induced DIC, AT III-
heparin complex therapy, 979, 
980 
recombinant human SOD in 
endotoxemia, 915, 917 
RES Stimulation to protect against DIC, 
1002, 1005 
scintigraphic evaluation of posttraumatic 
liver function, 776 
Fibrinolysis 
aprotinin membrane protective action, 
intraoperative histamine 
liberation, 961 
cascade, 318 
lung, microvascular bed, cell 
interactions in septic shock, 
115 
functional determinants, pig, endotoxic 
shock, 395-399 
kallikrein-kinin system components in 
ARDS after Polytrauma, 737 
methylprednisolone pretreatment effects 
in porcine E. coli endotoxemia, 
873, 877 
pulmonary vascular permeability, 
305-307 
septic patients, 383-387 
Syndrome, DIC, 971, 972, 974 
tests for, 383-386 
Fibrinopeptide A , endotoxin and 
overwhelming inflammatory response 
of early sepsis, 372, 373 
Fibrinopeptides, specific, and Proteinase 
inhibitor complex, immunologic 
determination, humans, 971, 972, 
974 
Fibrin split products, 395, 654 
Fibronectin, 886 
capillary endothelial cells, 158 
endotoxin and overwhelming 
inflammatory response of early 
sepsis, 372 
plasma, and abdominal sepsis prognosis, 
716, 720, 722, 723 
Fluid Substitution, hemorrhagic shock, 
phase-related vascular reactivity, 
cats, 147-148 
Fluorescent products, lipid peroxidation, 
hypovolemic-traumatic shock, dogs, 
345-349 
Flurbiprofen, 365 
FMLP, 508, 510 
Free radical scavengers 
C3 and IgG breakdown in Peritonitis 
exudate, 527 
cardiopulmonary response to endotoxin, 
sheep, 885-888 
a-mercaptopropionyl glycine in 
hemorrhagic shock, 897-903 
Fructose infusion, kidney function in sepsis, 
603 
Gabexate mesilate, 309 
amino acid concentrations, serum, 
experimental endotoxin shock, 
596, 597 
D-Galactosamine, 1070, 1071 
Gamma-scintillation with DTPA, alveolar 
permeability, 324-327 
Index /1119 
Gangrene, gas. See Immunoglobulin profiles 
and PMN-elastase in septic gas 
gangrene 
Gas exchange 
alveolar permeability increased by PMA-
stimulated neutrophils, rabbits, 
ARDS, 326, 327 
hemofiltration and survival time, porcine 
acute endotoxic shock, 823, 825 
septicemia (£. coli), Goettingen pig, 
185-188 
Gas gangrene. See Immunoglobulin profiles 
and PMN-elastase in septic gas 
gangrene 
Gastric mucosa ulceration 
ultrastructure after septic shock, rat, 
151-155 
irreversible changes, 154-155 
parietal cells, 152, 153 
stress ulcer diseases, correlation 
with, 151 
surface epithelial cells, 153, 154 
WEB 2086 (PAF antagonist) and, 919 
Gastrin, 380 
Gastrointestinal tract 
decontamination, 827-832 
endotoxin-induced damage, and WEB 
2086 (PAF antagonist), 919-922 
PAF antagonist inhibition of induced 
shock, 430 
Gel filtration, positive inotropic factor as 
myocardial stimulant, 254 
Gentamicin and methylprednisolone, animal 
models for shock, 836-840 
Glasgow Coma Scale, 644-646 
Global Index, Polytrauma, 744-746 
Glucagon, glucose turnover in sepsis, 
552-553, 556, 559 
Glucocorticoids, glucose turnover in sepsis, 
552-553, 559 
Glucose 
concentrations, kidney metabolism in E. 
coli sepsis, 602, 604 
deficiency, calcium antagonists in 
shock/ischemia, 1066 
metabolism 
liver dysfunction in MSOF, altered 
cell-cell interactions, 563-565 
Polytrauma, 744 
respiratory quotient ( C 0 2 / 0 2 
exchange ratio) in shock, 
619-621 
oxidation, metabolic abnormalities in 
sepsis, 536-539, 545 
turnover, metabolic abnormalities in 
sepsis, 547-552 
mediators, 552-557 
Glucose-insulin-potassium infusions, kidney 
metabolism in E. coli sepsis, 
604 
ß-Glucuronidase, platelet, activated C3 in 
DIC in septic shock, fulminant 
meningococcal meningitis, 272, 273 
Glutamate pyruvate transaminase activity, 
endotoxin, dose-related effects on 
RES, 408, 410, 411 
Glutamine and glutamic acid concentrations, 
serum, experimental endotoxin 
shock, 598 
alpha!-acid Glycoprotein, prognostic index 
in sepsis, 634, 635, 716, 717 
Goris multiple organ failure score, 
626-628, 664, 1026, 1027, 1029 
Granulocytes. See PMN entries 
Growth hormone, 380 
Gut decontamination, early ventilatory 
support, 786 
H7, 122 
HA 1004, 122 
Hageman factor. See Factor XII (Hageman 
factor) 
Haidane effect, 615 
Hannover Polytrauma Score, 38 
Haptoglobin, and abdominal sepsis 
prognosis, 716 
Heart 
inotropic plasma factor 
positive, hypovolemic shock, 
253-257 
isolated, effect of L M W plasma fraction, 
hypovolemic traumatic shock, 
dog, 231-234 
L V systolic pressure, 233, 234 
negative inotropism, shock plasma 
ultrafiltrates, 231-234 
isolated, rabbit, endotoxin inotropic 
effects, 225-230 
overperformance in septic shock, 
259-263 
1120 / Index 
in septic shock, awake sheep, 237-245 
artifact rejection, 239-242 
contractility, 238 
hemodynamic parameters, respiratory 
influence, 243 
pressure/volume loop, 238, 244 
sonomicrometer L V dimension, 
237-243 
see also Cardiac entries; Myocardial 
entries 
Heart cells, cultured, effects of 
Pseudomonas aeruginosa toxins, rat, 
247-251 
and cardiac function, 247-251 
endotoxins, 247, 249 
type A , 247-251 
immunoglobulins, Pseudomonas, 
protection, 247-249, 251 
Heart dysfunction, septic shock, human, 
191-197 
cf. dog. 196 
end diastolic volume index, 193, 194, 
197 
cf. endotoxin effect on healthy 
volunteers, 196-197 
hemodynamic profiles, 192-193 
interleukin-2, 197 
left ventricular ejection fraction, 
193-196 
mechanisms, 194-196 
myocardial depressant 
substance/factor, 194-196 
right ventricle, 194 
stroke volume index, 193, 194, 196, 
197 
TNF, 197 
Heart function changes, septic shock, 
chacma baboon {Papio ursinus), 
207-215, 217-222 
cardiac Output, 207, 210-215, 219-222 
heart rate, 208, 210-215 
tachycardia and cardiac volume, 
214-215, 217-222 
left ventricular compliance, 221, 222 
left ventricular ejection fraction, 207, 
210, 211, 213-215 
left ventricular end diastolic volume, 
207, 209-214, 217, 219-222 
left ventricular end systolic volume, 
207, 209-214, 219-222 
pulmonary capillary wedge pressure, 
217, 219-222 
stroke volume, 207, 210-214, 219, 
221-222 
systemic vascular resistance, 219, 220 
ventriculography, radionuclide, 
209-210, 218, 219 
Heart rate 
heart function changes, septic shock, 
chacma baboon (Papio ursinus), 
208, 210-215, 217-222 
a-mercaptopropionylglycine in 
hemorrhagic shock, 899, 900 
RA 642 effects on, acute hemorrhagic 
shock, 1094 
Hematocrit, recombinant human SOD in 
endotoxemia, 914-916 
Hemodynamics 
dopamine infusion, effect evaluation 
with systolic time intervals, 
1104-1105 
endotoxin, 390-391 
liver dysfunction in MSOF, altered cell-
cell interactions, 565 
methylprednisolone pretreatment effects 
in porcine E. coli endotoxemia, 
874, 876-877 
PVR, 874, 876-877 
PAF antagonists in endotoxin shock, 
933, 935 
PAF effects in sheep, 448-449 
septic shock/septicemia, 192-193 
Immunoglobulin and plasmapheresis 
therapy, 1025-1030 
pulmonary venous hemodynamics 
and gas exchange 
disturbances, Goettingen pig, 
186 
respiratory influence, awake sheep, 
243 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 472, 
479 
see also specific parameters 
Hemofiltration and survival time, porcine 
acute endotoxic shock, 821-826 
arachidonic acid metabolites, 823-825 
cardiac output, 822, 825 
extravascular lung water, 822, 823, 
825 
Index /1121 
gas exchange, 823, 825 
6-keto-PGF,a, 823, 825 
peripheral resistance, total, 822, 825 
thromboxane, 823-825 
Hemoglobin, respiratory quotient ( C 0 2 / 0 2 
exchange ratio) in shock, 608 
Hemolysin, Escherichia coli, 67-70 
Hemorrhagic shock 
calcium antagonists in shock/ischemia, 
1067 
cerebrocortical perfusion, RA642 
effects, 1091-1094 
oc-mercaptopropionylglycine, 
897-903 
Hemorrhagic shock, phase-related vascular 
reactivity, cats, 143-149 
autoregulation, 147, 148 
compensated shock, 144-148 
decompensated shock, 145-148 
electrical Stimulation, efferent, isolated 
intestinal vascular bed, 145 
fluid Substitution, 147-148 
noradrenaline, 146 
oxygen free radicals, 144, 148, 149 
permeability, capillary and postcapillary, 
143 
PMNs, 148, 149 
vascular tone, 143 
Heparin, 940 
Hepatocytes 
cystolic C a 2 + in, diltiazem and 
endotoxin-induced intracellular 
C a 2 + overload, 1055-1060 
endotoxin, dose-related effects on RES, 
408, 411 
liver dysfunction in MSOF, altered cell-
cell interactions, 563, 567, 568 
phorbol ester binding sites, 583-584 
protein kinase C and diacylglycerol 
accumulation, entodoxemia, rats, 
575-586 
in situ receptor autoradiography, 
579, 583-584, 586 
phorbol ester binding sites, 583-584 
see also Liver entries 
Hepatotoxin D-galactosamine, 1070, 1071 
Hernioraphy, 493 
Herniotomy, 1018, 1020 
HETE, cardiopulmonary response to 
endotoxin, eicosanoids in, sheep, 203 
5-HETE, 351 
15-HETE, 351 
Hetrazepine, WEB 2086 (PAF antagonist), 
925, 928 
High-density lipoproteins, 81 
Hip arthroplasty, total, high-dose 
corticosteroids to prevent C3a and 
C5a formation, 879-882 
Hirudin, neutrophils, thrombin-induced 
adhesion with endothelial cells, 103 
Hirudin/eglin C, recombinant, endotoxin 
shock, proteinase/protease inhibitor 
therapy, 937-942 
Hirudo medicinalis, 937 
HIS scoring system, 626-628, 645, 1026, 
1027, 1029 
Histamine, 941 
intraoperative liberation, aprotinin 
membrane protective action, 
959-963 
WEB 2086 (PAF antagonist), 
anaphylactic lung reaction, 926, 
927 
Histologie appearance, pulmonary fat 
embolism, 40 
Honeycomb cysts, 29, 32 
5-HT (Serotonin) 
lung injury in E. coli endotoxemia, 362, 
368 
platelet, activated C3 in DIC in septic 
shock, fulminant meningococcal 
meningitis, 272, 273 
Hyaline membrane disease, 29 
elastase-etrPI as early indicator, 690, 
691 
Hydrocortisone, 121, 122 
Hydrogen peroxide, 886, 888, 950 
eglin C ineffectiveness in endotoxin 
shock, 954-956 
lipid peroxidation, hypovolemic-
traumatic shock, dogs, 346 
Hydroxyethyl starch, volume replacement in 
ovine endotoxemia, 815-819 
cardiac index, 818, 819 
cf. crystalloids, 815-819 
lung lymph, 817, 818 
plasma colloid osmotic pressure, 
816-819 
pulmonary artery pressure, main, 816, 
817 
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Hydroxyl radical, 887, 950 
alveolar permeability increased by PMA-
stimulated neutrophils, rabbits, 
ARDS, 328 
eglin C ineffectiveness in endotoxin 
shock, 954-956 
4-Hydroxynonenal (HNE), 662, 663 
inflammation in surgical trauma, human, 
351-355 
lipid peroxidation, hypovolemic-
traumatic shock, dogs, 345-348 
PMNs in Sephadex inflammation model, 
rats, 351-355 
Chemotaxis, 351 
Superoxide anion production, 354, 
355 
Hydroxyurea, 887, 888 
Hyperalaninemia and lethality, endotoxin 
shock, 595, 597-599 
Hyperbaric oxygenation, 1008, 1010, 1013, 
1020 
Hypersensitivity, delayed-type. See Delayed 
type hypersensitivity 
Hypertension, pulmonary 
PAF effects in sheep, 450, 451 
thromboxane-mediated, E. coli 
hemolysin injury to, septicemia, 
67, 70 
vascular leakage, and complement 
activation, 283-286 
cf. pore-forming, Staphylococcus 
alpha-toxin, 286 
Hyperthermia, metabolic abnormalities in 
sepsis, 547 
Hyperventilation, respiratory quotient 
(C0 2 / 0 2 exchange ratio) in shock, 
615, 619-621 
Hypovolemic shock 
ARDS, 32, 33 
positive inotropic factor as myocardial 
stimulant, 253-257 
Hypovolemic traumatic shock, 228, 229 
lipid peroxidation, dogs, 345-350 
plasma fraction, L M W , effect on 
isolated heart, 231-234 
L V systolic pressure, 233, 234 
negative inotropism, shock plasma 
ultrafiltrates, 231-234 
Hypoxanthine levels, lipid peroxidation, 
hypovolemia-traumatic shock, dogs, 
346-349 
Hysterectomy, aprotinin membrane 
protective action, intraoperative 
histamine liberation, 959-963 
Ibuprofen, cardiopulmonary response to 
endotoxin, eicosanoids in, sheep, 
202, 203 
Ileus, MSOF prognostic indices, logistic 
regression analysis, 644 
IMAC, 702, 707-710 
Immune complexes, circulating, plasma, 
and abdominal sepsis prognosis, 
716 
Immune suppression/dysfunction, post-
trauma or surgery, 491-494 
early events, 507-511 
lymphocyte/monocyte ratio in survival, 
769 
monocyte-dependent Ig synthesis 
suppression, 513-516 
MSOF, biochemical analysis and 
scoring, 661-662 
T-cell mediated, Polytrauma, 517-521 
thymopentin for, 995-998 
trauma-induced cascade of cell-mediated 
immune effects, 495-505 
immunorestoration, 504-505 
Schema, 501, 503 
Immunoassay, automated homogenous 
enzyme immunoassay, elastase-a r 
antiproteinase complex, 
707-710 
cf. coated tube ELISA, 708-710 
Immunoelectrophoresis, crossed, C3 and 
IgG breakdown in Peritonitis 
exudate, 529, 531 
Immunoglobulin(s) 
IgA, Immunoglobulin profiles and PMN-
elastase in septic gas gangrene, 
1009, 1011 
IgG, 427-428 
breakdown, Peritonitis exudate, C3 
and, 527-532 
-deficiency Substitution, and P M N -
elastase in septic gas 
gangrene, 1007, 1012, 
1018-1020 
Index /1123 
IgM-enriched Igs (Pentaglobin), 
1031-1033, 1035, 1046, 1050 
in immune suppression, post-surgical or 
post-traumatic, 492 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769, 770 
plasma, and abdominal sepsis prognosis, 
716 
Pseudomonas, protection of cultured 
heart cells from effects of 
Pseudomonas aeruginosa toxins, 
rat, 247-249, 251 
synthesis 
and plasmapheresis therapy, 
hemodynamic effects during 
treatment for septic shock, 
1025-1030 
suppression after multiple trauma, 
513-516 
trauma-induced cascade of cell-
mediated immune effects, 
496, 497, 499, 501, 502 
therapeutic 
phagocytosis Stimulation, Peritonitis, 
1037-1041 
prophylactic, sepsis prevention after 
cardiac surgery, 1031-1035 
Immunoglobulin profiles and PMN-elastase 
in septic gas gangrene, 1007-1022 
aprotinin administration, 1008, 1012, 
1014-1016 
IgA, 1009, 1011 
IgG, 1009, 1011, 1012-1021 
IgG-deficiency Substitution, 1007, 1012, 
1018-1020 
dosage, 1018 
IgM, 1009, 1011 
primary cf. secondary, 1008 
Immunologie determination, humans, 
Proteinase inhibitor complexes, 
971-974 
Immunomodulation 
septic shock, 989-993 
thymopentin (TP-5), post-burn and 
postoperative sepsis, 995-998 
Indometacin, 120, 122, 131, 203, 365, 
502 
immune/cytotoxic processes, role in, 442 
Infarction, myocardial, 910, 972, 973 
Infection 
DIT marker in, 711-713 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769, 770, 
772 
Inflammation 
autodestruetive, complement activation, 
MSOF pathogenesis in septic 
shock, dogs, 296 
early, Schema, 456, 457 
pharmacologic Intervention points, 
457 
overwhelming, endotoxin role, 371-375 
pathways, corticosteroids, V A 
comparative study of severe 
sepsis, 850-851 
vs. sepsis as trigger, MSOF, 413-416 
in surgical trauma, 4-hydroxy-nonenal, 
351-355 
see also specific cell types and mediators 
Inflammatory cell activation, multiple 
system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring, 
655-661 
Inhaled antigen, WEB 2086 (PAF 
antagonist), anaphylactic lung 
reaction, 926, 928 
Injury Severity Score, 731 
dopamine infusion, effect evaluation 
with systolic time intervals, 
1102 
embolism, fat, pulmonary, 38 
phospholipase A as prognostic index, 
764 
Polytrauma, 744, 745 
scintigraphic evaluation of posttraumatic 
liver function, 776 
Insulin, 1060-1061, 1066 
infusion, kidney function in sepsis, 604 
metabolic abnormalities in sepsis, 538, 
547 
Intensive care unit assay, validity, elastase-
arantiproteinase complex, 
701-705 
correlation to MOF score, 704-705 
correlation to physician's Classification, 
703-704 
ELISA, 701-702 
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IMAC assay, 702 
7-Interferon, 772 
trauma-induced cascade of cell-mediated 
immune effects, 495, 497-504 
Interleukin-1, 11, 13, 114, 368, 428, 432, 
443, 467, 479, 486, 536, 850 
Ig synthesis suppression after multiple 
trauma, 513 
liver dysfunction in MSOF, altered cell-
cell interactions, 564, 568, 569 
pulmonary vascular permeability, 
305 
serum, and sepsis, prognosis/prognostic 
indices, 715-718 
trauma-induced cascade of cell-mediated 
immune effects, 495, 497-503 
Interleukin-2, 772, 990, 995, 996 
heart dysfunction, septic shock, human, 
197 
Ig synthesis suppression after multiple 
trauma, 513, 515 
immune/cytotoxic processes, role in, 
442 
trauma-induced cascade of cell-mediated 
immune effects, 496-503 
Interleukin-2 receptors 
immune suppression, post-surgical or 
post-traumatic, 492, 494 
multiple trauma, early events, 508, 509 
trauma-induced cascade of cell-mediated 
immune effects, 496, 501, 502 
InterIeukin-4 (BCGF), trauma-induced 
cascade of cell-mediated immune 
effects, 497 
Intestinal transit velocity, WEB 2086 (PAF 
antagonist), 919-922 
Intima. See Vascular intima in endotoxin 
shock 
Intraglobin, 1047, 1050 
Intra-tracheal pressure, lung injury in f . 
coli endotoxemia, 360, 361, 365 
Inverse ratio Ventilation 
early ventilatory support, 788, 789 
nifedipine for ARDS, 1087, 1090 
IP3, hepatocytes, protein kinase C and 
diacylglycerol accumulation, 
endotoxemia, 575 
Iron-dependent lipid peroxidation in 
cardiopulmonary arrest, 895 
Ischemia, myocardial 
acute, dynamics of prostacyclin and 
thromboxane, 907-911 
arrhythmias, 907 
Ischemia and circulatory system in MSOF, 
1075-1083 
ARDS, 1076, 1078, 1081, 1083 
pulmonary hypertension, 1078 
catecholamines, 1077 
central mechanisms, 1075-1079 
cardiac Output, 1076-1077, 1080, 
1082 
myocardial depressant factor, 1076, 
1077 
myocardium, reperfused, 1077 
oxygen delivery, 1075-1083 
peripheral mechanisms, 1079-1082 
capillary surface area reduction, 
1082 
oxygen extraction, 1079-1083 
regional blood flow, 1080-1081, 
1083 
see also Calcium antagonists in 
shock/ischemia 
Isoprinosine, 502 
Kadsurenone, 428, 485 
Kallikrein, 738, 741, 983 
circulation, peripheral, septic shock, 
171 
endotoxin interactions with plasma 
contact system factors, 401-404 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 469, 
474, 479 
Kallikrein-kinin system, 318 
in ARDS after Polytrauma, 737-742 
endotoxin, 389, 390, 392, 393 
pulmonary vascular permeability, 
305-307 
Ketanserin, 362 
Kidney 
complement activation, MSOF 
pathogenesis in septic shock, 
dogs, 294-296 
and dopamine, 1097-1099 
plasma flow, 1098 
failure, postoperative, 133-136 
metabolism in E. coli sepsis, 601-605 
ATP MgCl 2 , 602, 605 
glucose concentrations, 602, 604 
Index /1125 
glucose-insulin-potassium infusions, 
604 
lactate or fructose infusion, 603 
T A N concentrations, 601, 602, 604 
microthrombosis, endotoxin-induced, 
916 
PAF antagonist inhibition of induced 
shock, 429 
RES Stimulation to protect against DIC, 
1002, 1003 
Kininase II, 941 
Kininogen, 983, 986 
Kinins, 986-987 
cascade, lung microvascular bed, cell 
interactions in septic shock, 115 
see also Kallikrein-kinin system 
Kupffer cells, 78, 81, 294, 779, 1002, 1004 
endotoxin, dose-related effects on RES, 
408 
liver dysfunction in MSOF, altered cell-
cell interactions, 563, 564, 
566-571 
zymosan-induced MSOF, entodoxin 
plays no key role, 422 
L-652,731, 426, 428, 442, 485 
L-653,150, 428 
Lactate 
or fructose infusion, kidney metabolism 
in E. coli sepsis, 603 
hypovolemic-traumatic shock, dogs, 
346-349 
metabolism, liver, 744 
Polytrauma, 743, 745, 747 
Lactate dehydrogenase, lung, endotoxin-
induced microvascular endothelial 
injury, 93, 96 
Lactoferrin, pulmonary vascular 
permeability, 307, 308 
Laser Doppler flowmetry, RA642, effects 
on cerebrocortical perfusion, acute 
hemorrhagic shock, 1091-1094 
Lavage therapy, C3 and IgG breakdown in 
Peritonitis exudate, 530, 531 
Leukocyte(s) 
count 
methylprednisolone pretreatment, 
endotoxemia, 875, 876 
recombinant human SOD in 
endotoxemia, 914, 915, 917 
total, 699, 700 
-induced injury with zymosan, lung, 
73-76 
phagocytic activity in sepsis/infection, 
diiodotyrosine (DIT) as marker 
for, 711-713 
and TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 469, 
470, 475-477, 480 
see also specific types 
Leukocyte neutral Proteinase inhibitor, 
945-950 
Leukopenia, WEB 2086 (PAF antagonist), 
anaphylactic lung reaction, 926 
Leukostasis 
alveolar permeability increased by PMA-
stimulated neutrophils, rabbits, 
ARDS, 325, 326 
lipid peroxidation in hypovolemic shock, 
349-350 
lung in shock, 4-5, 7-8 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 473, 
474, 480 
Leukotrienes, 70, 351 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 203, 204 
complement activation, pulmonary 
hypertension and vascular 
leakage, 286 
early ventilatory support, 785 
L T B 4 , sepsis, 535, 536 
L T C 4 , 432 
lung injury in E. coli endotoxemia, 362 
synthesis, RA642 effects on 
cerebrocortical perfusion, acute 
hemorrhagic shock, 1094 
Lipid A. See Antibodies, anti-LPS and anti-
lipid A , determination with 
immunoblotting 
Lipid peroxidation, 662, 663 
hypovolemic-traumatic shock, dogs, 
345-350 
inhibition in cardiopulmonary arrest, 
dogs, 891-895 
see also Oxygen radicals 
Lipocortin, 123 
Lipooxygenase inhibition, AA-861, 131 
Lipopolysaccharide, S. abortus equi, 119, 
121; see also Antibodies, anti-LPS 
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and anti-lipid A, determination with 
immunoblotting 
Lipoprotein, high-density, 81 
Lipoprotein lipase suppression, TNF, 464 
Liver 
complement activation, MSOF 
pathogenesis in septic shock, 
dogs, 293-294, 296 
enzymes, serum, scintigraphic evaluation 
of posttraumatic liver function, 
776-779 
failure, complement activation and 
endotoxin role, sepsis, 277 
lactate metabolism, 744 
leukostasis, TNF induction of organ 
changes in chronic lymph fistuia, 
473, 474, 480 
perfused, sepsis effect on metabolism, 
589-592 
scintigraphic evaluation of posttraumatic 
function, 775-780 
SGOT, TNF induction of changes in 
chronic lymph fistuia, sheep, 469, 
474, 475, 480 
sinusoidal macrophages, endotoxin, 
dose-related effects on RES, 408 
see also Hepatocytes; Kupffer cells 
Liver dysfunction in MSOF, altered cell-cell 
interactions, 563-571 
glucose metrabolism, 563-565 
hemodynamics, 565 
hepatocytes, 563, 567, 568 
interleukin-1, 564, 568, 569 
Kupffer cells, 563, 564, 566-571 
paracrine amplification, 563, 569 
polyunsaturated fatty acids, 569-571 
Prostaglandins, 564, 568, 569 
protein metabolism, 565, 567, 568 
thromboxane, 569 
TNF, 564, 568-570 
Low-flow states, respiratory quotient 
(C0 2 / 0 2 exchange ratio) in shock, 
615, 616 
Luminol-dependent chemiluminescence, 
339-344 
cf. zymosan-activated, 341 
Lung(s), 3-10 
anaphylactic rection, WEB 2086 (PAF 
antagonist), 925-929 
endothelial sWelling, 8, 9, 11 
endotoxin-induced microvascular 
endothelial injury, 91-97 
Escherichia coli hemolysin injury, 
septicemia in, 67-70 
transmembrane pores, 69 
injury, P M A , SOD after, 945-949 
isolated, pulmonary vascular 
permeability, 309-311 
leukocyte-induced injury with zymosan, 
73-76 
leukostasis, 4-5, 7-8 
microvascular bed, cell interactions in 
septic shock, 113-118 
organ failure, 10-14; see also 
ARDS 
PAF antagonist inhibition of induced 
shock, 429 
perfusion, decreased, 5-6 
platelet activation, 6, 7 
zymosan-induced MSOF, endotoxin 
plays no key role, 421-423 
Lung edema. See Pulmonary edema in 
shock 
Lung epithelial lining fluid, 792, 793 
Lung injury in E. coli endotoxemia, 
357-368 
cats, vagotomized, 361 
intra-tracheal pressure, 360, 361, 365 
mediators, 358, 362-366 
pulmonary artery pressure, 360, 364, 
365, 368 
pulmonary compliance, 358-361, 367 
pulmonary resistance, 358, 359 
transpulmonary pressure, 358-361 
Lung lymph flow 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 202-204 
free radical scavengers and 
cardiopulmonary response to 
endotoxin, 885 
hydroxyethyl starch, volume replacement 
in ovine endotoxemia, 817, 818 
PAF antagonists in endotoxin shock, 
933-935 
PAF effects in sheep, 447, 450 
permeability, pulmonary vascular, 
mediators, 308 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 469, 
473, 475, 479 
Index /1127 
Lung water, extravascular. See 
Extravascular lung water (EVLW) 
Lupus erythematodes cells, 52, 53 
Lymph fistuia. See TNF, induction of organ 
changes in chronic lymph fistuia, 
sheep 
Lymphocyte(s) 
counts, immune suppression, post-
surgical or post-traumatic, 492 
/monocyte ratio in Polytrauma survival, 
prognosis/prognostic indices, 
769-772 
see also B cell(s); T cell(s) 
Lysolecithin acyl-transferase (LAT), 122, 
123, 455 
a2-Macroglobulin, plasma, and abdominal 
sepsis prognosis, 716, 717, 720 
Macrophage(s) 
activation/induction 
elastase-arPI complex and 
neopterin, plasma levels, 687 
and TNF productin in shock, PAF, 
485-488 
alveolar, chemotactic factors, 20 
ARDS, posttraumatic, prognosis, 679 
hepatic. See Kupffer cells 
multiple system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring, 
657, 659, 660 
origins of, lung, microvascular bed, cell 
interactions in septic shock, 
113-114, 118 
phospholipase A source, 757, 763, 767 
pulmonary intravascular 
endotoxin-induced microvascular 
endothelial injury, 92 
endotoxin shock, 78, 80, 81 
vascular intima in endotoxin shock, 78, 
80, 81 
Macrophage-activating factor, trauma-
induced cascade of cell-mediated 
immune effects, 497 
Magnesium and calcium antagonists in 
shock/ischemia, 1072 
Magnesium chloride, ATP-, kidney function 
in sepsis, 602, 605 
Major basic protein, 432, 488 
Malondialdehyde, 662, 663, 910 
leukocyte-induced lung injury, 74, 75 
lipid peroxidation, hypovolemic-
traumatic shock, dogs, 346-348 
Mannheim Peritonitis Index, 723 
Mast cell chymase, 937, 941, 942 
Meclophenamate, 203 
Meconium aspiration, elastase-arPI as 
early indicator, 690, 691 
Membrane protective action, intraoperative 
histamine liberation, aprotinin, 
959-963 
Meningitis 
elastase-arPI as early indicator, 
690-692 
fulminant meningococcal, activated C3 
in DIC in septic shock, 271-274 
Mepacrine, 120 
Mepyramine, 362, 926 
a-Mercaptopropionyl glycine, hemorrhagic 
shock, 897-903 
Mesenteric blood flow, bums, enteric 
translocation of microorganisms, 
377-380 
Metabolic abnormalities in sepsis, 
535-542, 545-559 
ARDS, 535, 537, 538 
branched-chain amino acids, 539, 540, 
617 
carbon dioxide, arterial, 537, 538 
dichloracetic acid therapy, 540, 
541 
glucose turnover, 547-552 
mediators, 552-557 
hyperthermia, 547 
insulin, 538, 547 
L T B 4 , 535, 536 
mitochondrial pyruvate dehydrogenase, 
538-540, 549, 550 
MOSF, 535-542 
oxidation of glucose cf. fats, 536-539, 
545 
PGF2cx/PGE2 ratio, 535, 536 
proteolysis, excessive, 540-542 
rat experimental model, 546-547 
Superoxides, 535, 536 
TPN, 537, 538 
Metabolic imbalance, multiple system organ 
fai 1 ure, postoperative/posttrauma, 
biochemical analysis and scoring, 
663-664 
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Metabolie rate, septic shock, heart 
overperformance in, 260-262 
Methylmethacrylate cement, 879, 880 
Methylprednisolone, pretreatment effects in 
porcine E. coli endotoxemia, 
873-877 
coagulation, 873 
fibrinolysis, 873, 877 
hemodynamics, 874, 876-877 
PVR, 874, 876-877 
proteolysis cascades, 873, 877 
V A study, 873 
Methylprednisolone for septic shock with 
ARDS, 861-863 
with gentamicin, dogs, E. coli shock, 
animal model development for 
shock, 836-837 
adrenal gland role, 838-839 
cf. baboons, 836-840 
rationale, 837-838 
Methysergide, 362 
Microangiopathy, diabetic, 1009 
Microatelectasis, early ventilatory Support, 
787 
a2-Microglobulin 
immune suppression, post-surgical or 
post-traumatic, 492 
kallikrein-kinin system components in 
ARDS after Polytrauma, 738, 
739, 742 
Microvascular integrity, extravascular lung 
water, altered fluid regimen, 
advanced septic shock with acute 
respiratory failure, 806 
Microvascular permeability. See under 
Permeability 
Milano Sepsis Score, 634-636 
complement activation, endotoxin role in 
sepsis, 278-280 
Minimal pulmonary dysfunction, 52 
Mitochondrial function 
calcium antagonists in shock/ischemia, 
1066 
pyruvate dehydrogenase, metabolic 
abnormalities in sepsis, 538-540, 
549, 550 
Monocyte(s), 989, 991, 993 
count, multiple trauma, early events, 
508, 509 
-dependent Ig synthesis suppression after 
multiple trauma, immune 
suppression/dysfunetion, 513-516 
/lymphocyte ratio as prognostic factor, 
Polytrauma, 769-772 
synthesis, a,-protease inhibitor, 948 
see also Macrophage(s) 
Monokine synthesis factor, 499 
Monolayer-filter membrane system, 
endothelium permeability and, 
128-131 
MPP 
pulmonary vascular resistance, ARDS in 
septicemia, 175-178 
pulmonary venous hemodynamics and 
gas exchange disturbances, E. 
coli septicemia, Goettingen pig, 
185, 186 
MTDQ-DA antioxidant, myocardial 
ischemia, 907-911 
Mucosal integrity, burns, enteric 
translocation of microorganisms, 
377-380 
Multiple system organ failure (MOF, 
MOSF, MSOF) 
in acute pancreatitis, C3a and C5a, 
265-268 
terminal complement complexes, 
266, 267 
ARDS, septic, 57-60 
prognosis, 59 
C3a, 880 
ceruloplasmin changes, 331-337 
C-reactive protein, 335, 336 
number of organs involved, 333, 
334, 336 
complement activation in, septic shock, 
291-296 
elastase-a,-PI complex and neopterin, 
plasma levels, 
683-687 
endotoxin and proteases, septicemia, 
315-321 
diagnostic criteria for MSOF, 316 
PFI index, 317-321 
epidemiology, 783-784 
Goris score, 1026, 1027, 1029 
ischemia and circulatory system in, 
1075-1083 
Index /1129 
liver dyfunction, 563-571 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769, 770 
metabolic abnormalities in sepsis, 
535-542 
muscle p0 2 role, critically ill patients, 
138-140 
phospholipase A as prognostic index, 
766 
prevention, zymosan-induced Peritonitis, 
decontamination, G l tract, 
827-832 
prognostic indices, 643-647 
sepsis vs. inflammation as trigger, 
Polytrauma, 413-416 
ventilatory support, early, 784-789 
zymosan-induced, no endotoxin role, 
419-423 
Multiple system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring, 
649-665 
coagulation cascade, fibrinolysis, and 
kallikrein system, 652-654 
complement cascade, 650-651 
endotoxin, 654-655 
immune suppression/dysfunction, 
661-662 
inflammatory cell activation, 655-661 
metabolic imbalance, 663-664 
organ function parameters, 664-665 
stages, 649 
target structure degradation, 662-663 
Multiple trauma. See Polytrauma; Trauma 
Muscle 
p0 2 role, critically ill patients, MOF, 
137-142 
MOFscores, 138-140 
survival, 139, 141 
skeletal, diltiazem and endotoxin-
induced intracellular Ca 2 + 
overload, 1054-1061 
smooth, spasm, calcium antagonists in 
shock/ischemia, 1066 
Mycostatin, 378 
Mycotoxin-induced shock, PAF antagonist 
inhibition of induced shock, 431 
Myeloperoxidase, pulmonary vascular 
permeability, 307, 308 
Myocardial contractility, depressed, 
dopamine infusion effect evaluation 
with systolic time intervals, 1101 
Myocardial depressant factor, 253, 261, 
262, 431, 1068 
heart dysfunction, septic shock, human, 
194-196 
ischemia and circulatory system in 
MSOF, 1076, 1077 
Myocardial infarction, 910, 972, 973 
Myocardial ischemia 
acute, dynamics of prostacyclin and 
thromboxane, 907-911 
arrhythmias, 907 
Myocardium, reperfused, ischemia and 
circulatory system in MSOF, 1077 
Negative chronotropic effect, a-
mercaptopropionylglycine in 
hemorrhagic shock, 902 
Neonatal respiratory distress Syndrome, 
exogenous Surfactant, 797 
Neopterin, 477, 657, 659, 660 
ARDS, posttraumatic, prognosis, 
674-679 
and elastase-arPI complex, plasma 
levels in MSOF, 683-687 
immune suppression, post-surgical or 
post-traumatic, 492-494 
Polytrauma, 745, 747 
Neuroleptics, 755 
Neurologie function and lipid peroxidation 
inhibition in cardiopulmonary arrest, 
891-895 
Neutrophils. See PMN entries 
Nicardipine, endotoxin shock, 1071 
Nifedipine, 1060 
ARDS, 1087-1090 
endotoxin shock, 1070, 1071 
Nimodipine, traumatic shock, 1067, 1068 
Nine Rule, total burn surface estimation, 
1102, 1103 
Nitrogen mustard, 887 
Nivadipine, endotoxin shock, 1070 
NK cells, 989, 991 
PAF antagonist effects, 443-444 
Noradrenaline/norepinephrine 
hemorrhagic shock, phase-related 
vascular reactivity, cats, 146 
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metabolic abnormalities in sepsis, 547, 
548 
ONO, 6240, 428, 931 
Opsonins, C3 and IgG breakdown in 
Peritonitis exudate, 527-532 
Organ failure, multiple. See Multiple 
system organ failure (MOF, MOSF, 
MSOF) 
Organ failure, postoperative, tissue oxygen 
debt ( V 0 2 deficit) as determinant, 
133-136 
survivors cf. nonsurvivors, 136 
Osmotic pressure. See Plasma colloid 
osmotic pressure 
Oxidation of glucose cf. fats, metabolic 
abnormalities in sepsis, 536-539, 
545 
Oxygen 
arterial tension, endotoxin effect, 
391-392 
delivery 
endotoxin, inotropic effect in isolated 
rabbit heart, 227 
ischemia and circulatory system in 
MSOF, 1075-1083 
extraction 
ischemia and circulatory system in 
MSOF, 1079-1083 
peripheral, septic shock, heart 
overperformance in, 260-262 
see also Respiratory quotient 
( C 0 2 / 0 2 exchange ratio) in 
shock 
hypoxia, early ventilatory support, 
784-787 
and luekocyte-induced lung injury, 74, 
75 
skeletal muscle p 0 2 and multiple organ 
failure, 137-142 
supply 
peripheral, pulmonary vascular 
resistance, ARDS in 
septicemia, 175, 177, 179 
-uptake relationship, septic shock, 
181-183 
tissue oxygen debt (V0 2 ) deficit and 
postoperative organ failure, 
133-136 
survivors cf. nonsurvivors, 136 
utilization, circulation, peripheral, septic 
shock, 163, 167-169 
Oxygen, hyperbaric, 1008, 1010, 1013, 
1020 
Oxygen radicals 
ARDS, exogenous Surfactant, 791, 793 
cerulosplasmin changes in MSOF and 
ARDS, 331-332, 337 
endotoxemia, 886-888 
hemorrhagic shock, phase-related 
vascular reactivity, cats, 144, 
148, 149 
leukocyte-induced lung injury, 73, 75, 
76 
lung 
endotoxin-induced microvascular 
endothelial injury, 95 
microvascular bed, cell interactions 
in septic shock, 114 
multiple organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring, 
656, 661 
permeability, pulmonary vascular, 
mediators, 305-306, 311, 312 
PMN activation, 850 
scavenging. See Free radical scavengers 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 470, 
476, 477 
see also Lipid peroxidation; specific 
types 
Pancreatic cysts, C-reactive protein as 
prognostic index, 726 
Pancreatitis 
C3a and C5a in MSOF, 265-268 
terminal complement complexes, 
266, 267 
C-reactive protein as prognostic index, 
725-728 
extravascular lung water, large volume 
replacement with crystalloids, 809 
Papillary muscle, guinea pig, 231-233 
Papio ursinus, septic shock, heart function 
changes, 207-215, 217-222 
Paracrine amplification, liver dysfunction in 
MSOF, altered cell-cell interactions, 
563, 569 
Parietal cells, gastric mucosa ulceration, 
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Ultrastructure after septic shock, rat, 
152, 153 
Passive sensitization, WEB 2086 (PAF 
antagonist), anaphylactic lung 
reaction, 926, 928 
Pediatric systemic infection, elastase-arPI 
as early indictor, 
689-693 
PEEP 
nifedipine for ARDS, 1087, 1090 
ventiiatory support, early, 788-789 
Pelvis fracture and pulmonary fat embolism, 
39-41 
Pentaglobin, 1031-1033, 1035, 1046, 1050 
Perfusion, decreased, lung in shock, 5-6 
Perfusion circuit, endotoxin, inotropic effect 
in isolated rabbit heart, 226, 227 
Peripheral circulation. See Circulation, 
peripheral, septic shock 
Peripheral resistance, total 
hemofiltration and survival time, porcine 
acute endotoxic shock, 822, 825 
septic shock, heart overperformance in, 
260, 262 
Peritoneal exudate cells, therapeutic Igs, 
phagocytosis Stimulation in 
Peritonitis, 1038 
Peritonitis 
C-reactive protein as prognostic index, 
725-728 
endotoxin and overwhelming 
inflammatory response of early 
sepsis, 372-374 
exudate, C3 and, immunoglobulin G 
breakdown, 527-532 
therapeutic Ig Stimulation of 
phagocytosis, exudate cells, 1038 
zymosan-induced, decontamination, G l 
tract, 827-832 
Peritonitis Index, 643 
Permeability 
alveolar 
cf. capillary permeability, 323, 
328-329 
gamma-scintillation with DTPA, 
detection, 324-327 
PMA-stimulated neutrophils, rabbit 
ARDS, 323-329 
capillary 
endothelial cells, 157, 159 
and postcapillary, hemorrhagic 
shock, phase-related vascular 
reactivity, cats, 143 
complement and pulmonary 
hypertension, 283-286 
endothelial, bacterial toxins and calcium 
effects, 127-131 
microvascular, 92-93, 96 
circulation, peripheral, septic shock, 
167 
free radical scavengers and 
cardiopulmonary response to 
endotoxin, 885, 886, 888 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 
472, 473, 479-481 
Permeability, pulmonary vascular, 
mediators, 305-312 
E. coli hemolysin injury, septicemia, 67, 
69-70 
eicosanoids/arachidonic acid cascade, 
305, 306, 308, 312 
lung lymph flow, 308 
thromboxane, 310 
granulocytes (PMNs) and macrophages 
as source, 307-311 
isolated rabbit lung, 309-311 
oxygen radicals, 305-306, 311, 312 
PAF effects, sheep, 447, 451 
PMN-elastase-aj-protease inhibitor, 
308-310 
proteases, 306, 309, 312 
inhibitor Eglin C, 311 
PFI index, 317-321, 653, 731-735 
pH 
isolated heart, effect of L M W plasma 
fraction in hypovolemia traumatic 
shock, 234 
respiratory quotient ( C 0 2 / 0 2 exchange 
ratio) in shock, 608, 609, 
615-617 
Phagocytic index, RES Stimulation to 
protect against DIC, 1004 
Phagocytosis assay, 508, 510 
Phagocytosis Stimulation, Peritonitis, 
therapeutic Immunoglobulins, 
1037-1041 
IgG, 1041 
IgM, 1039, 1041 
Phentolamine, 553, 555, 557, 558 
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Phenylephrine, protein kinase C and 
diacylglycerol accumulation in 
hepatocytes, endotoxemia, 579-
581 
Phorbol esters, protein kinase C and 
diacylglycerol accumulation in 
hepatocytes, endotoxemia, 576, 578, 
579, 582, 586 
Phorbol myristate acetate, 123 
lung injury, Superoxide dismutase, 
945-949 
-stimulated neutrophils, rabbit ARDS, 
permeability, alveolar, 323-329 
Phosphatidate phosphohydrolyase, 576 
Phosphatidylcholine and phosphatidyl 
glycerol, exogenous Surfactant, 792 
Phospholipase A 
lethality correlation, 759-761, 764, 
765 
severely ill patients, 
prognosis/prognostic indices, 
757-761, 763-768 
sources, 757, 763, 767 
Phospholipase A 2 , 123, 432 
C, protein kinase C and diacylglycerol 
accumulation in hepatocytes, 
endotoxemia, 575, 576 
calcium antagonists in shock/ischemia, 
1066, 1071 
PMN activatin, 850, 851, 855 
Phospholipid reacylation, burns, PAF 
inhibitor effect, scalded pig, 455, 
459, 461 
Pia arterioles, RA642, effects on 
cerebrocortical perfusion, acute 
hemorrhagic shock, 1093 
PIP 2, hepatocytes, protein kinase C and 
diacylglycerol accumulation, 
endotoxemia, 575 
Plasma colloid osmotic pressure 
and extravascular lung water 
altered fluid regimen, advanced 
septic shock with acute 
respiratory failure, 803-808 
large volume replacement with 
crystalloids, 810-812 
hydroxyethyl starch, volume replacement 
in ovine endotoxemia, 816-819 
Plasma contact system factors, in vitro 
interactions, endotoxin, 401-405 
Plasma flow, renal, dopamine and renal 
function, 1098 
Plasma fraction, L M W , effect on isolated 
heart, hypovolemic traumatic shock, 
dog, 231-234 
LV systolic pressure, 233, 234 
negative inotropism, shock plasma 
ultrafiltrates, 231-234 
Plasmapheresis, 1025-1030 
Plasma proteins, abdominal sepsis, 
prognosis/prognostic indices, 
719-724 
Plasma Substitution in septic shock, 
humans, antithrombin III, 965-968 
Plasma suppressive activity, thymopentin 
(TP-5) in post-burn and postoperative 
sepsis and immunodeficiency 
Syndrome, 996-998 
Plasmin, methylprednisolone pretreatment, 
endotoxemia, 874, 875 
Plasmin-a2-antiplasmin complex, 
immunologic determination, humans, 
971 
Plasminogen 
consumption, aprotinin membrane 
protective action, intraoperative 
histamine liberation, 961, 962 
kallikrein-kinin system components in 
ARDS after polytrauma, 738, 740 
Plasminogen activator, 654 
inhibitor, and fibrinolysis, 383-386, 
395-399 
urokinase-type, neutrophils, thrombin-
induced adhesion with endothelial 
cells, 109 
Plasminogen activator, tissue (tPA), 576, 
578, 579, 582, 586, 938 
binding sites, hepatocytes, 583-584 
endotoxic shock, fibrinolytic function 
determinations, pig, 395-399 
fibrinolysis, 383-386 
neutrophils, thrombin-induced adhesion 
with endothelial cells, 109 
Platelet(s) 
activation, lung in shock, 6, 7 
aggregation, calcium antagonists in 
shock/ischemia, 1066 
aprotinin membrane protective action, 
intraoperative histamine 
liberation, 960, 961 
Index /1133 
count 
methylprednisolone pretreatment, 
endotoxemia, 875, 876 
RES Stimulation to protect against 
DIC, 1002, 1005 
endotoxin-induced DIC, AT III-heparin 
complex therapy, 980 
ß-glucuronidase, activated C3 in DIC in 
septic shock, fulminant 
meningococcal meningitis, 272, 
273 
5-HT, activated C3 in DIC in septic 
shock, fulminant meningococcal 
meningitis, 272, 273 
recombinant human SOD in 
endotoxemia, 914-915, 917 
Platelet activating factor (PAF), 13, 14, 
481, 660 
antagonists, inhibition of induced shock, 
427-433 
C5a and, 366 
calcium, 366 
chronically instrumented sheep, effect 
on, 447-451 
generation during shock, 426-427 
glucose turnover in sepsis, 556-558 
immune/cytotoxic processes, role in, 
441-443 
infusion in animals, cf. shock, 
425-426 
lung injury in E. coli endotoxemia, 358, 
366-368 
macrophage/monocyte induction and 
TNF production in shock, 
485-488 
PAF antagonist effects, 485, 486 
neutrophil aggregation, 108, 109, 367 
Platelet activating factor antagonists 
burns, 455-461 
cytotoxic processes, effects, 443-444 
endotoxic shock, 931-935 
inhibition of induced shock, inhibition of 
PAF-generated feedback cycles, 
432-433 
neutrophils, thrombin-induced adhesion 
with endothelial cells, 108 
ONO-6240, 428, 931 
see also BN 52021; WEB 2086 (PAF 
antagonist); specific antagonists 
Platelet-derived growth factor, neutrophils, 
thrombin-induced adhesion with 
endothelial cells, 109 
PMN(s) (neutrophils, granulocytes), 20-22, 
972 
activation, 21, 850 
and leukostasis, lipid peroxidation, 
hypovolemic-traumatic shock, 
dogs, 349-350 
see also specific activation products 
aggregation, PAF, 367 
ARDS, 18-20, 31-33 
posttraumatic, prognosis, 673, 674, 
678, 679 
ceruloplasmin changes in MSOF and 
ARDS, 331 
complement, 20 
MSOF pathogenesis in septic shock, 
dogs, 293, 296 
pulmonary hypertension and vascular 
leakage, 283, 284 
early ventilatory support, 784 
eglin C ineffectiveness in endotoxin 
shock, 954-956 
-endothelial cell adherence, 157, 159 
bacterial endotoxin role, 123-124 
proadherent factor, 106-107, 109 
thrombin-induced, 101-109 
generation, chemiluminescence-inducing 
radicals, porcine septic shock, 
339, 341 
hemorrhagic shock, phase-related 
vascular reactivity, cats, 148, 149 
4-hydroxy-nonenal, 351-355 
Igs, therapeutic, phagocytosis 
Stimulation in Peritonitis, 
1039-1041 
lung injury, 11-12, 74, 75 
MSOF 
Polytrauma, 414 
postoperative/posttrauma, 
biochemical analysis and 
scoring, 653, 655, 657-660 
multiple trauma, early events, 507, 508, 
510, 511 
phospholipase A source, 757, 763, 767 
and pulmonary vascular permeability, 
307-311 
Superoxide radical production by, 
recombinant human SOD in 
endotoxemia, 913, 917 
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zymosan-induced MSOF, endotoxin 
plays no key role, 422 
see also Elastase-a,-antiproteinase 
complex; Oxygen radicals; PMN 
elastase 
PMN elastase, 331, 731-735, 937, 941, 
942 
ARDS, post-traumatic, prognosis, 
674-679 
eglin C ineffectiveness in endotoxin 
shock, 953-957 
porcine shock, Proteinase inhibitor, 
leukocyte neutral, 945-950 
eglin C in septic shock, 945-948 
PMA lung injury, SOD after, 
945-949 
prognostic index in sepsis, 634, 635 
see also Elastase-a,-antiproteinase 
complex; Immunoglobulin profiles 
and PMN-elastase in septic gas 
gangrene 
PMN elastase-arantitrypsin complex, 
antithrombin III and plasma 
Substitution in septic shock, 966-968 
Pneumocytes, type II, 52, 53 
Pneumonia 
Ig prophylactic therapy after cardiac 
surgery, 1034 
pediatric, elastase-arPI as early 
indicator, 690-692 
phospholipase A as prognostic index, 
765-768 
Polyphloretin, 363 
Polytrauma 
ARDS, kallikrein-kinin system, 737-742 
biochemical and hormonal parameters, 
743-745, 746-749 
monocyte/lymphocyte ratio as prognostic 
factor, 769-772 
PFI index, 731-735 
phospholipase A as prognostic index, 
763-768 
Polytrauma Score, T-cell-mediated immune 
suppression after Polytrauma, 517 
Polyunsaturated fatty acids, liver 
dysfunction in MSOF, altered cell-
cell interactions, 569-571 
Positive inotropic factor as myocardial 
stimulant, ion exchange 
chromatography, 254-255 
Potassium 
and cardiac function, Pseudomonas 
aeruginosa toxins, 247-249 
infusion, kidney, function in sepsis, 
604 
PR 1501, 443 
PR 1502, 443 
Prealbumin, plasma, and abdominal sepsis 
prognosis, 720, 722 
Predictors. See Prognosis/prognostic indices 
Prednisone, 377 
Preallikrein, 986 
in ARDS after Polytrauma, 737, 738 
and endotoxin 
interactions with plasma contact 
system factors, 402-404 
and overwhelming inflammatory 
response of early sepsis, 372 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 469, 
474, 475, 479 
Pressure/volume loop, heart Performance 
during septic shock, awake sheep, 
238, 244 
Proadherent factor, neutrophils, thrombin-
induced adhesion with endothelial 
cells, 106-107, 109 
Proenzyme Functional Inhibition (PFI) 
Index, 317-321, 653, 731-735 
Progesterone, 122 
Prognosis/prognostic indices 
ARDS, posttraumatic, plasma levels of 
mediators, 673-679 
macrophages, 679 
cf. non-ARDS, 676, 677, 679 
C-reactive protein in pancreatitis and 
Peritonitis, 725-728 
elastase-a,-PI, early indicator of 
pediatric systemic infection, 
689-693 
interleukin-1, serum, and sepsis, 
715-718 
lymphocyte/monocyte ratio in 
Polytrauma survival, 769-772 
MSOF, logistic regression analysis, 
643-647 
PFI index, Polytrauma, 731-735 
cf. elastase, 731-735 
phospholipase A in severely ill patients, 
757-761, 763-768 
Index /1135 
plasma proteins, abdominal sepsis, 
719-724 
scintigraphic evaluation of posttraumatic 
liver function, 775-780 
sepsis, 633-636 
TNF, serum, 715-718 
Prolactin, sepsis, 751, 753, 754, 756 
Promethazine, 1070 
Properdin factor B, plasma, and abdominal 
sepsis prognosis, 720 
Propranolol, 553, 555, 557, 558 
Prostacyclin (PGI2), 119-123 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 202, 203 
circulation, peripheral, septic shock, 168 
complement activation, pulmonary 
hypertension and vascular 
leakage, 285-286 
liver dysfunction in MSOF, altered cell-
cell interactions, 589 
lung injury, endotoxin-induced, 366 
microvascular endothelium, 92-94, 
96, 97 
myocardial ischemia, 907-911 
neutrophils, thrombin-induced adhesion 
with endothelial cells, 109 
Prostaglandines), 380, 660-661 
burns, PAF inhibitor effect, scalded pig, 
455, 459, 460 
D 2 , lung injury in E. coli endotoxemia, 
362, 365, 366 
E 2 , 429, 661, 662 
Ig synthesis suppression after 
multiple trauma, 513, 515 
liver dysfunction in MSOF, altered 
cell-cell interactions, 564, 
568, 569 
lung, endotoxin-induced injury, 
92-94, 96, 97, 359, 363 
trauma-induced cascade of cell-
mediated immune effects, 
497-504 
F 2 a 
lung injury in E. coli endotoxemia, 
359, 362-366 
/PGE 2 ratio, metabolic abnormalities 
in sepsis, 535, 536 
glucose turnover in sepsis, 552 
H 2 , 122 
6-keto-PGF,a, hemofiltration and 
survival time, porcine acute 
endotoxin shock, 823, 825 
Prostaglandin endoperoxide synthetase, 910 
Prostaglandin synthetase, 1071 
Protease(s) 
in MSOF due to septicemia, endotoxin, 
315-321 
permeability, pulmonary vascular, 
mediators, 306, 309, 312 
inhibitor Eglin C, 311 
see also specific proteases 
<xrProtease inhibitor, 331, 725-726 
ARDS, posttraumatic, prognosis, 674, 
676 
kallikrein-kinin system components in 
ARDS after Polytrauma, 738, 740 
monocyte synthesis, 948 
and PAF antagonist in induced shock, 
431-432 
Proteinase inhibitor complexes 
immunologic determination, humans, 
971-974 
leukocyte neutral, ELISA, 945-946 
PMN elastase complex, porcine 
shock, 945-950 
PMN-derived, eglin C ineffectiveness in 
endotoxin shock, 954-956 
see also Elastase-a,-antiproteinase 
complex; specific Proteinase 
Inhibitors 
Proteinase/protease inhibitor therapy, 
hirudin/eglin C, recombinant, 
endotoxin shock, 937-942 
Protein C, 654 
Protein kinase C, 122, 123 
and diacylglycerol accumulation, 
endotoxemia, rat hepatocytes, 
575-586 
in situ reeeptor autoradiography, 
579, 583-584, 586 
phorbol ester binding sites, 583-584 
Protein metabolism, liver 
dysfunction in MSOF, altered cell-cell 
interactions, 565, 567, 568 
perfused, sepsis effect on metabolism, 
589-592 
Proteolysis 
cascades, methylprednisolone, 
pretreatment effects in porcine E. 
coli endotoxemia, 873, 877 
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excessive, metabolic abnormalities in 
sepsis, 540-542 
Prothrombin, 319 
methylprednisolone pretreatment, 
endotoxemia, 874, 875 
Providencia pettgeh, 420 
Pseudomonas, 831 
aeruginosa 
cytotoxin, 68, 119, 120, 128, 129 
cytotoxin, effect on cultured heart 
cells, rat, 247-251 
protection by Pseudomonas Igs, 
247-249, 251 
septic shock, chemiluminescence-
inducing radicals, pig, 
339-334 
Immunoglobulin and plasmapheresis 
therapy, hemodynamic effects 
during treatment for septic shock, 
1025-1029 
oxygen supply-uptake relationship, 
septic shock, 182 
Pulmonary. See also Cardiopulmonary 
entries; Lung entries 
Pulmonary artery, sheep, neutrophils, 
thrombin-induced adhesion with 
endothelial cells, 102 
Pulmonary artery pressure 
cf. blood flow, pulmonary vascular 
resistance, ARDS in septicemia, 
175-179 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 202 
extravascular lung water, altered fluid 
regimen, advanced septic shock 
with acute respiratory failure, 804 
hydroxyethyl starch, volume replacement 
in ovine endotoxemia, 816, 817 
lung injury in E. coli endotoxemia, 360, 
364, 365, 368 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 471 
Pulmonary artery wedge pressure and 
extravascular lung water 
altered fluid regimen, advanced septic 
shock with acute respiratory 
failure, 803-808 
large volume replacement with 
crystalloids, 809-812 
Pulmonary capillary pressure, pulmonary 
venous hemodynamics and gas 
exchange disturbances, E. coli 
septicemia, Goettingen pig, 185, 186 
Pulmonary capillary wedge pressure, heart 
function changes, septic shock, 
chacma baboon (Papio ursinus), 
217, 219-222 
Pulmonary circulation, ARDS C3a and 
alveoli in, post-trauma, 45 
Pulmonary contusion, ARDS, C3a and 
alveoli in, post-trauma, 46, 47 
Pulmonary dysfunction, minimal, 52 
Pulmonary edema in shock, 9, 28-29, 31 
arachidonic acid cascade in ARDS, 
306-307, 309-311 
capillary pressure, 28 
see also Extravascular lung water; 
Permeability 
Pulmonary failure prediction, elastase-cti-PI 
complex and neopterin, plasma 
levels, 683, 684, 687 
Pulmonary function, muscle p0 2 role, 
critically ill patients, 139 
Pulmonary hypertension. See Hypertension, 
pulmonary 
Pulmonary resistance, lung injury in £. coli 
endotoxemia, 358, 359 
Pulmonary vascular pressure, nifedipine for 
ARDS, 1089 
Pulmonary vascular resistance 
ARDS in septicemia, 175-179 
CI, 175-179 
MPP, 175-178 
oxygen supply, peripheral, 175, 177, 
179 
pulmonary artery pressure cf. blood 
flow, 175-179 
endotoxin response, 390 
a-mercaptopropionylglycine in 
hemorrhagic shock, 901, 902 
recombinant hirudin/eglin C, endotoxin 
shock, 939, 941 
Pulmonary venous hemodynamics and gas 
exchange disturbances, E. coli 
septicemia, Goettingen pig, 185-188 
atrial pressure, left, 185, 186 
CI, 185, 186 
hemodynamic parameters, 186 
Index /1137 
MPP, 185, 186 
pulmonary capillary pressure, 185, 186 
Quin 2, 1055-1056 
RA642, acute hemorrhagic shock, rats, 
cerebrocortical perfusion, 1091-1904 
Radicals, chemiluminescence-inducing, 
septic shock, pigs, 339-344; see also 
Oxygen radicals 
Reanimation, MSOF prognostic indices, 
logistic regression analysis, 644, 646 
Receptor autoradiography, in situ, 
hepatocyte protein kinase C and 
diacyglycerol accumulation, 
endotoxemia, 579, 583-584, 586 
Red blood cell acetylcholinesterase, 
activated C3 in DIC in septic shock, 
fulminant meningococcal meningitis, 
272, 274 
Regional blood flow, ischemia and 
circulatory system in MSOF, 
1080-1081, 1083 
Relaxing factors, endothelium-derived, 157 
Respiratory distress, nebulized 
corticosteroid, 867-871 
Respiratory distress Syndrome, neonatal, 
exogenous Surfactant, 797; see also 
ARDS 
Respiratory failure 
early ventilatory support, 784-789 
embolism, fat, pulmonary, 37, 41 
extravascular lung water, altered fluid 
regimen, 803-808 
Respiratory quotient ( C 0 2 / 0 2 exchange 
ratio) in shock, 607-610, 613-617, 
619-621 
amino acid metabolism, 619-621 
base excess, 613, 614, 619 
expired minute volume, 613, 614, 
619-621 
fat metabolism, 619-621 
glucose metabolism, 619-621 
hemoglobin, 608 
hyperventilation, 615, 619-621 
low-flow states, 615, 616 
pH, 608, 609, 615-617 
RRE, 613-617 
TBRE, 613-617 
Reticuloendothelial system 
endotoxin, dose-related effects, 407-411 
liver clearance, scintigraphic evaluation 
of posttraumatic function, 
775-780 
Stimulation to protect against DIC, 
1001-1005 
Rhematoid arthritis, 332 
C3a, 299 
Right ventricle, heart dysfunction, septic 
shock, human 194 
RO-193,430, 704 
Ronipamil, traumatic shock, 1067, 1068 
Salmonella 
abortus equi, 408 
antibodies, anti-LPS and anti-lipid A , 
determination with 
immunoblotting, 1044, 1046 
LPS, 119, 121 
enteriditis, 426-428, 430, 1054 
minnesota, antibodies, anti-LPS and 
anti-lipid A , determination with 
immunoblotting, 1044-1049 
typhimurium, 428 
Sanarelli-Schwartzman reaction, 1003, 1005 
SAPS scoring system, 626-628, 1026, 
1027, 1029 
dopamine infusion, effect evaluation 
with systolic time intervals, 1102 
Scintigraphic evaluation of posttraumatic 
liver function, prognosis/prognostic 
indices, 775-780 
Scoring Systems 
cardiogenic/septic shock, 625-630 
CI and SVR, 625, 626 
elastase a,-PI complex and neopterin, 
plasma levels in MSOF, 683-687 
prognostic value of antithrombin III and 
endotoxin in sepsis, 637 
lethality, 639, 640 
thrombocyte counts, 637-641 
see also Multiple system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring; 
Prognosis/prognostic indices; 
specific Systems 
S-creatinine, MSOF prognostic indices, 
logistic regression analysis, 644, 645 
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SDZ 63-441, 429 
Secretin, 380 
Sensitization, passive, WEB 2086 (PAF 
antagonist), anaphylactic lung 
reaction, 926, 928 
Sensorium, altered, corticosteroids in severe 
sepsis, 841, 843, 853-855 
Sephadex inflammation model, rats, 
4-hydroxy-nonenal, 351-355 
Sepsis 
DIT marker in, 711-713 
early, overwhelming inflammatory 
response, endotoxin role, 
371-375 
elastase-arPI as early indicator, 
690-692 
endocrine secretion patterns, 751-756 
A D H , 751, 753, 755, 756 
prolactin, 751, 753-754, 756 
thyroid hormones, 751-756 
endotoxin in complement activation, 
277-281 
kidney metabolism in, 601-605 
metabolic abnormalities, See Metabolic 
abnormalities in sepsis 
multiple organ system failure, 413-416 
ARDS, 61-65 
prognostic indexes, 633-636 
IL-1, 715-718 
plasma proteins, 719-724 
Proteinase inhibitor complex, 
immunologic determination, 
humans, 972-974 
scintigraphic evaluation of posttraumatic 
function, liver, 775-780 
severe, corticosteroids in, 840-844, 
847-855 
see also Immunoglobulin profiles and 
PMN-elastase in septic gas 
gangrene 
Septicemia 
antibodies, anti-LPS and anti-lipid A , 
determination with 
immunoblotting, 1048-1050 
ARDS, pulmonary vascular resistance, 
175-179 
coagulation cascade, 383-387 
E. coli hemolysin injury to lung, 67-70 
transmembrane pores, 69 
fibrinolysis, 383-387 
gas exchange, disturbed, 185-188 
MSOF and, endotoxin and proteases in, 
315-321 
T cell changes, 989, 990 
Septic shock 
antithrombin III and plasma Substitution, 
965-968 
ARDS, 30-33 
corticosteroids in, 857, 860-864 
PMN migration, 30-31 
cardiac dysfunction, 191-197, 207-215, 
217-222, 237-245, 259-263 
cardiac work, 260-262 
chemiluminescence-inducing radicals, 
pig, 339-344 
complement activation in MSOF, 
291-296 
DIC in, and C3, 271-274 
dopamine infusion, effect evaluation 
with systolic time intervals, 
1101-1105 
eglin C, 945-948 
extravascular lung water 
altered fluid regimen, 803-808 
large volume replacement with 
crystalloids, 809-813 
immunoglobulin therapy 
after cardiac surgery, 1034 
and plasmapheresis, 1025-1030 
immunomodulation, 989-993 
lung microvascular bed, cell 
interactions, 113-118 
metabolic rate, 260-262 
oxygen extraction, peripheral, 
260-262 
oxygen supply-uptake relationship, 
181-183 
peripheral circulation, 163-171 
peripheral resistance, total, 260, 262 
scoring Systems, 625-630 
CI and SVR, 625, 626 
TNF, 463-465 
Septic Syndrome, definition, 857-860 
Serotonin. See 5-HT (Serotonin) 
Serratia marcescens, anti-LPS and anti-lipid 
A antibodies, determination with 
immunoblotting, 1044-1048 
SGOT, liver, TNF induction of organ 
changes in chronic lymph fistuia, 
469, 474, 475, 479 
Index /1139 
SH-groups, a-mercaptopropionylglycine in 
hemorrhagic shock, 897, 902, 903 
Silver sulfadiazine, 378 
Simplified Acute Physiologie Score, 280, 
635 
c-sis, neutrophils, thrombin-induced 
adhesion with endothelial cells, 
109 
Small intestine, complement activation, 
MSOF pathogenesis in septic shock, 
dogs, 293-294, 296 
Sodium exeretion, dopamine and renal 
function, 1097-1099 
Sodium polyanethol sulfonate-induced 
shock, 1001-1005 
Somatomedin C, Polytrauma, 743, 745, 747 
Somatostatin, glucose turnover in sepsis, 
553, 556 
Sonomicrometer L V dimension, heart 
Performance during septic shock, 
awake sheep, 237-243 
Spleen, zymosan-induced MSOF, endotoxin 
plays no key role, 421 
SRI 63-072, 428, 485 
SRI 63-441, 368,428,485 
SRI 63-675, 557 
SSS scoring System, 626-628, 664, 1026, 
1027, 1029 
dopamine infusion, effect evaluation 
with systolic time intervals, 1102 
Polytrauma, 744-746 
Staphylococcus 
aureus, 420, 868 
alpha toxin, 68, 69, 119, 120, 123, 
124, 127-130, 286 
xlyosus, 420 
Streptococcus, 831 
Streptomycin, G l tract decontamination, 
MOF prevention, 828-832 
Stress ulcer diseases, correlation with, 
gastric mueosa ulceration, 
ultrastructure after septic shock, rat, 
151 
Stroke volume 
heart function changes, septic shock, 
chacma baboon {Papio ursinus), 
207, 210-214, 219, 221-222 
a-mercaptopropionylglycine in 
hemorrhagic shock, 900, 902 
RA642, effects on cerebrocortical 
perfusion, acute hemorrhagic 
shock, 1094 
septic shock, human, 193, 196, 197 
Superoxide anion, 886 
generation, PAF and, 488 
4-hydroxy-nonenal, 354, 355 
lipid peroxidation, hypovolemic-
traumatic shock, dogs, 346 
metabolic abnormalities in sepsis, 535, 
536 
PMN production 
corticosteroid, nebulized, in 
experimental respiratory 
distress, 869, 870 
recombinant human SOD in 
endotoxemia, 913, 917 
Superoxide dismutase, 887 
PMA lung injury, 945-949 
recombinant human, in E. coli 
endotoxemia, rat, 913-917 
Surface epithelial cells, gastric mueosa 
ulceration, ultrastructure after septic 
shock, rat, 153, 154 
Surfactant, ARDS C3a and alveoli in, post-
trauma, 44, 45 
Surfactant, exogenous 
acute high-permeability lung edema, 
791-795 
ARDS, 29 
cf. neonatal RDS, 797 
aspiration trauma, experimental, rabbit, 
797-800 
phosphatidylcholine and phosphatidyl 
glycerol, 792, 798 
porcine, 798 
Surfactometer, bubble, 792 
Systemic lupus erythematosus, C3a, 299 
Systemic vascular resistance, 625, 626 
and heart function changes, septic 
shock, chacma baboon (Papio 
ursinus), 219, 220 
Immunoglobulin and plasmapheresis 
therapy, hemodynamic effects 
during treatment for septic shock, 
1026-1029 
a-mercaptopropionylglycine in 
hemorrhagic shock, 900-902 
septic shock, 163-166, 168, 170 
Tachycardia and cardiac volume, heart 
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function changes, septic shock, 
chacma baboon (Papio ursinus), 
214-215, 217-222 
T A N concentrations, kidney metabolism in 
E. coli sepsis, 601, 602, 604 
Target structure degradation, multiple 
system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring, 
662-663 
T cell(s) 
immune suppression/dysfunction, 
Polytrauma, 517-521 
multiple trauma, early events, 507, 508 
septicemia/septic shock, 989, 990 
subsets, 508, 510, 518-520 
Ig synthesis suppression after 
multiple trauma, 513-514, 
516 
MSOF, postoperative/posttrauma, 
biochemical analysis and 
scoring, 661 
PAF and, 442 
in septic shock, 989, 991, 993 
thymopentin (TP-5), post-burn and 
postoperative sepsis and 
immunodeficiency Syndrome, 
995, 998 
trauma-induced cascade of cell-
mediated immune effects, 
496-505 
T-cell replacing factor, 497 
Tebonin, effect in burns, 455-461 
Terminal complement complex 
acute pancreatitis, 266, 267 
pulmonary hypertension and vascular 
leakage, 283-286 
Theophylline, 755 
Thiobarbituric acid reactive material, lipid 
peroxidation, hypovolemic-traumatic 
shock, dogs, 345, 346 
Thiol groups, a-mercaptopropionylglycine 
in hemorrhagic shock, 897, 902, 903 
Thrombin, 367, 937, 941, 942 
MSOF, postoperative/posttrauma, 653 
Thrombin-antithrombin III complex 
antithrombin III and plasma Substitution 
in septic shock, 966-968 
immunologic determination in humans, 
971-974 
Thrombin-induced adhesion with endothelial 
cells, neutrophils, 101-109 
Thrombocyte counts, prognostic value in 
sepsis, 637-641 
Thromboplastin, aprotinin membrane 
protective action, intraoperative 
histamine liberation, 961, 962 
Thromboxane, 429 
alveolar permeability increased by PMA-
stimulated neutrophils, rabbits, 
ARDS, 328 
burns 
enteric translocation of 
microorganisms, 379 
PAF inhibitor effect, scalded pig, 
455, 459, 460 
cardiopulmonary response to endotoxin, 
eicosanoids in, sheep, 201-204 
circulation, peripheral, septic shock, 168 
complement activation, pulmonary 
hypertension and vascular 
leakage, 285 
early ventilatory support, 786 
eglin C ineffectiveness in endotoxin 
shock, 955 
hemofiltration and survival time, porcine 
acute endotoxic shock, 823-825 
liver dysfunction in MSOF, altered cell-
cell interactions, 569 
lung, endotoxin-induced microvascular 
endothelial injury, 92 
lung injury in E. coli endotoxemia, 359, 
362-367 
and hypertension, 67, 70 
myocardial ischemia, 907-911 
PAF antagonists in endotoxin shock, 935 
permeability, pulmonary vascular, 
mediators, 310 
TNF, induction of organ changes in 
chronic lymph fistuia, sheep, 469, 
474, 475, 479 
Thromboxane receptor blockade, lung injury 
in E. coli endotoxemia, 366, 367 
Thromboxane synthetase inhibition, lung 
injury in E. coli endotoxemia, 
365-366 
Thymopentin (TP-5) immunomodulation, 
post-burn and postoperative sepsis 
and immunodeficiency Syndrome, 
995-998 
Index /1141 
Thymostimulin (TP-1), immunodulation in 
septic shock, 990-993 
Thyroid hormones 
and leukocyte phagocytic activity, DIT 
and 
T 3 , 712 
T 4 , 711-712 
Polytrauma, 743, 745 
T3, 745, 748 
T4, 744, 745, 748 
T B G , 744, 745, 749 
TSH, 744, 745, 749 
sepsis, 751-756 
T3, 751-756 
T4, 752-754 
TSH, 752, 753, 755 
TISS, 643, 645 
Tissue oxygen debt ( V 0 2 deficit) as 
determinant, organ failure, 
postoperative, 133-136 
survivors cf. nonsurvivors, 136 
Total parenteral nutrition, 377 
metabolic abnormalities in sepsis, 537, 
538 
Transfer factor, immunomodulation in 
septic shock, 990-993 
Transferrin, plasma, and abdominal sepsis 
prognosis, 720, 721 
Transpulmonary pressure, lung injury in E. 
coli endotoxemia, 358-361 
Trauma 
endotoxin and overwhelming 
inflammatory response of early 
sepsis, 372-374 
-induced cascade of cell-mediated 
immune effects, immune 
suppression/dysfunction, 
495-505 
immunorestoration, 504-505 
Schema, 501, 503 
cf. multiple system organ failure, 58-60 
see also Multiple system organ failure, 
postoperative/posttrauma, 
biochemical analysis and scoring; 
Polytrauma 
Trauma score, 643 
Traumatic shock 
calcium antagonists in shock/ischemia, 
1067-1068 
hypovolemic, 228, 229 
PAF antagonist inhibition of induced 
shock, 431 
Trifluorperazine, 120, 122, 1070 
Trimethoprim, G l tract decontamination, 
MOF prevention, 828-832 
Tumor necrosis factor (TNF, cachectin), 13, 
14, 114, 368, 432, 444, 536, 661, 
850, 851 
administration, metabolic abnormalities 
in sepsis, 550, 551 
circulation, peripheral, septic shock, 169 
discovery, 463 
endotoxin as Stimulus, 463, 464 
glucose turnover in sepsis, 555 
heart dysfunction, septic shock, human, 
197 
lipoprotein lipase suppression, 464 
liver dysfunction in MSOF, altered cell-
cell interactions, 564, 568-570 
lung injury, endotoxin-induced 
microvascular endothelial, 91, 
95-96 
production and macrophage/monocyte 
induction in shock, PAF, 
485-488 
PAF antagonist effects, 485, 486 
pulmonary vascular permeability, 
305 
in septic shock, 463-465 
serum, and sepsis, prognosis/prognostic 
indices, 715-718 
WEB 2086 (PAF antagonist), 919-921 
window phenomenon with PAF, 
921-922 
Tumor necrosis factor, induction of organ 
changes in chronic lymph fistuia, 
sheep, 467-481 
disseminated intravascular coagulation, 
479, 480 
elastase-a, -anti-proteinase commplex, 
470, 477-478, 480 
hemodynamics, 472, 479 
cf. human, 470, 477 
cf. in vitro, 470, 477 
kallikrein, 469, 474, 479 
leucocyte role, 469, 470, 475-477, 480 
leucostasis, liver, 473, 474, 480 
liver SGOT, 469, 474, 475, 480 
lung lymph, 469, 473, 475, 479 
oxygen radicals, 470, 476, 477 
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permeability, microvascular, 472, 473, 
479-481 
prekallikrein, 469, 474, 475, 479 
pulmonary artery pressure, 471 
thromboxane, 469, 474, 475, 479 
Typhoid fever, 852 
Tyrosine, amino acid concentrations, serum, 
experimental endotoxin shock, 598 
•U46619, 362, 368 . 
U74006F, 891-895 
Ulceration, gastric mucosa 
ultrastructure after septic shock, 
151-155 
and stress ulcer disease, 151 
and WEB 2086 (PAF antagonis^), 919 
Ultraviolet-absorption spectra, positive 
inotropic factor as myocardial 
stimulant, 255, 256 
Urea, MSOF prognostic indices, logistic 
regression analysis, 644-646 
Urokinase-type Plasminogen activator, 
neutrophils, thrombin-induced 
adhesion with endothelial cells, 109 
U.S. Veterans Administration, sepsis 
studies, corticosteroids, 840-844, 
847-855, 873 
Vascular intima in endotoxin shock, 77-87 
cell origins and replacefnent, 78-80 
endothelial injury, grading, 84-85 
endotoxin transport and elimination, 81 
generalized inflammation, 85-87 
aorta, 85, 86 
non-endothelial cells, 77-78 
macrophages, 78, 80, 81 
ultrastructural alterations, eariy, 82-84 
Vascular permeability. See Permeability 
Vascular tone, hemorrhagic shock, phase-
related vascular reactivity, cats, 143 
Vasopressin (antidiuretic hormone), 379 
hepatocytes, protein kinase C and 
diacylglycerol accumulation in 
endotoxemia, 576, 579-581, 
584-586 
sepsis, 751, 753, 755, 756 
Ventilatory support, early 
inversed ratio Ventilation, 788, 789 
multiple organ failure with acute 
respiratory failure, 784-789 
PEEP, 788-789 
Ventricular pressure cf. perfusion flows, 
endotoxin, inotropic effect in isolated 
rabbit heart, 227, 228 
Ventriculography, radionuclide, heart 
function changes in septic shock, 
cha^ma bajjoon (Papio ursinus), 
209-210, 218, 219 
Verapamil, 1060 
endotoxin shock, 1068, 1069 
pretreatment, calcium antagonists in 
shock/ischemia, 1067 % 
Virchow's triad, 851 
Vitamin E 
leukocyte-induced lung injury, 74-76 
lipid peroxidation inhibition in 
cardiopulmonary arrest, 893-895 
W7, 120 
WEB 2086 (PAF antagonist), 426, 428, 
429, 442, 485 
anaphylactic lung reaction, guinea pig, 
925-929 
endotoxin shock effects, 931-933, 935 
gastrointestinal tract damage, endotoxin-
induced, 919-922 
hetrazepine, 925 
WEB 2170, 928 
Weibel-Palade bodies, 83 
White blood cell count, 725, 728 
Wilhelmy tensiometer, 800 
Xanthine-oxidase, 349 
Zymosan 
-induced Peritonitis, decontamination, G l 
tract, 827-832 
leukocyte-induced lung injury 73-76 
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